



Vaccines and Global Health: The Week in Review
16 April 2022 :: Issue 653
Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

*Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted and the elements of each edition are presented as a set of blog posts at <https://centerforvaccineethicsandpolicy.net>. **This blog allows full text searching of over 23,000 entries.***

Comments and suggestions should be directed to
David R. Curry, MS
Editor and
Executive Director
Center for Vaccine Ethics & Policy
david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: *If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.*

Support this knowledge-sharing service: *Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.*

Contents [click to move among sections]

:: [Coronavirus \[COVID-19\] - WHO](#)

:: **Error! Reference source not found.** :: [Organization Announcements](#)

:: [Journal Watch](#)



SAGE April 2022 meeting highlights - WHO

11 April 2022

SAGE Meeting of 4-7 April 2022

PDF: https://cdn.who.int/media/docs/default-source/immunization/sage/sage-pages/sage_april2022meetinghighlights_11apr2022_final.pdf?sfvrsn=c2bd9f68_1

(Full report will be published in the Weekly Epidemiological Record on 10.06.2022, and only the wording of the full report should be considered as final)

Session 1 – Global & Regional Reports

Report from the WHO Department of Immunization, Vaccines & Biologicals

- The speed of the COVID-19 vaccine rollout has been unprecedented with nearly every country introducing the vaccine in under 12 months.
- Available data of COVID-19 vaccine effectiveness against the Omicron variant generally show waning immunity against infection but high and more sustained effectiveness against severe disease and death, especially after booster doses. Data remain very limited for some of the WHO EUL vaccines.
- To date, 21 countries remain below 10% population coverage, leaving at high risk the most vulnerable populations. Among countries eligible for support through the COVAX Advance Market Commitment (AMC) strategy at least 43 have set population targets at 70% or higher and only a small number have targets below 40% of their population.
- However, available data indicate that coverage among the high priority groups is insufficient to provide the needed protection against severe disease and death. Health worker coverage is 65% overall, with coverage below 50% in some regions (Non-AMC member states), and coverage of older adults is 69% going as low as 24% in some regions.
- Disruptions to routine immunization programmes persist, including the ongoing delay of at least one campaign in 37 countries as of 10 January 2022, putting millions of children at risk of disease outbreaks. Large and disruptive outbreaks of measles have occurred in at least 19 countries during the past 12 months.
- COVID-19 vaccination response and investments offer important opportunities that are being leveraged to restore and strengthen immunization programmes and enhance their resilience.

WHO Regional Updates

- National immunization programmes in all six WHO regions were adversely impacted by the COVID-19 pandemic through declining immunization coverage and surveillance quality, though the magnitude of the impact varied between and within regions.
- The European region is also facing a challenge due to the ongoing war in Ukraine and the resulting large population displacement. The WHO Regional Office and partner agencies are taking measures to mitigate the risks of vaccine-preventable disease outbreaks such as measles, polio, and COVID-19, while also ensuring continued delivery of critical medical supplies and services.
- All countries are implementing measures to restore vaccination coverage, with several having identified innovative strategies for catch up vaccination.
- The rollout of COVID-19 vaccination is progressing in all regions, though vaccine uptake varies between and within regions and disproportionately lower vaccination coverage has been observed in low- and low-middle income countries. Vaccine hesitancy and low risk perception are further affecting the uptake of COVID-19 vaccination in several countries.

Gavi report

- Reaching the zero-dose children through the building of resilient health systems remains a top priority of the Alliance in the Gavi strategy 2021-2025 (Gavi 5.0) and is estimated to account for over half the incremental impact of Gavi investments during the strategy period.
- A funding window for the rollout of malaria vaccines will be opened in the second half of 2022 to enable initial vaccine introductions in 2023.
- Gavi expressed concern over the 13% decline of global HPV vaccine coverage in 2020 due to COVID-19 disruptions, attributing this issue primarily to school closures and limited supply. It was acknowledged that a recommendation for a single dose regimen has the potential to accelerate introductions and reduce operational costs and complexity.
- The COVAX facility has sufficient supply available for all AMC countries to achieve the WHO 70% coverage target by June 2022. The COVAX Vaccine Delivery Partnership is supporting countries to overcome barriers and to achieve national coverage targets.

Session 2 – Immunization Agenda 2030 and catch-up vaccination

- SAGE was presented with evidence of the impact of the COVID-19 pandemic on national immunization programmes mainly due to service delivery disruptions.
- The urgent need to close resulting immunity gaps was recognized, as was the importance of supporting the recovery and resilience of immunization programmes and mitigating the risk of vaccine-preventable disease outbreaks.
- SAGE recommended that countries use the COVID-19 pandemic and COVID-19 vaccination rollout as a transformative opportunity to establish resilient immunization programmes and strengthen primary health care. Among the specific areas identified were health worker vaccination, immunization logistics and registries, surveillance, data and communications.
- The document “Guiding Principles for recovering, building resiliency, and strengthening of immunization in 2022 and beyond” was endorsed and recommended for dissemination to regional and national immunization technical advisory groups so that it may be adapted and used for their local context.

[The full summaries for the sessions below are available at the PDF link above]

Session 3 – Hepatitis A vaccination

Session 4 – COVID-19 vaccines

Session 5 – Typhoid conjugate vaccination

Session 6 – Human Papillomavirus vaccination

Session 7 – Poliovirus vaccines

.....

[One-dose Human Papillomavirus \(HPV\) vaccine offers solid protection against cervical cancer](#)

11 April 2022

News release

The 4-7 April convening of the WHO Strategic Advisory Group of Experts on Immunization (SAGE) evaluated the evidence that has been emerging over past years that single-dose schedules provide comparable efficacy to the two or three-dose regimens.

SAGE's review concluded that a single-dose Human Papillomavirus (HPV) vaccine delivers solid protection against HPV, the virus that causes cervical cancer, that is comparable to 2-dose schedules. This could be a game-changer for the prevention of the disease; seeing more doses of the life-saving jab reach more girls...

"The HPV vaccine is highly effective for the prevention of HPV serotypes 16 & 18, which cause 70% of cervical cancer," said Dr Alejandro Cravioto, SAGE Chair. "SAGE urges all countries to introduce HPV vaccines and prioritize multi-age cohort catch up of missed and older cohorts of girls. These recommendations will enable more girls and women to be vaccinated and thus preventing them from having cervical cancer and all its consequences over the course of their lifetimes."

SAGE recommends updating dose schedules for HPV as follows:

- one or two-dose schedule for the primary target of girls aged 9-14
- one or two-dose schedule for young women aged 15-20
- Two doses with a 6-month interval for women older than 21.

Immunocompromised individuals, including those with HIV, should receive three doses if feasible, and if not at least two doses. There is limited evidence regarding the efficacy of a single dose in this group.

WHO's recommendations will be updated following further consultation across stakeholders...

Globally, the uptake of the life-saving vaccine has been slow, and coverage in countries much lower than the 90% target. Consequently, in 2020 global coverage with 2 doses was only 13%. Several factors have influenced the slow uptake and low coverage of HPV vaccines including supply challenges, as well as the programmatic challenges and costs related to delivering a two regimen to older girls who are not typically part of childhood vaccination programs. Added to this has been the relatively high cost of HPV vaccines, particularly for middle-income countries...

The option for a single dose of the vaccine is less costly, less resource intensive and easier to administer. It facilitates implementing catch-up campaigns for multiple age groups, reduces the challenges linked to tracing girls for their second dose and allows for financial and human resources to be redirected to other health priorities."

.....
.....

COVID - IHR (2005 Emergency Committee

[Statement on the eleventh meeting of the International Health Regulations \(2005\) Emergency Committee regarding the coronavirus disease \(COVID-19\) pandemic](#)

13 April 2022

Statement [Excerpts]

The eleventh meeting of the Emergency Committee convened by the WHO Director-General under the International Health Regulations (2005) (IHR) regarding the coronavirus disease (COVID-19) pandemic took place on Monday 11 April 2022...

The Secretariat presented on the current status of the COVID-19 pandemic and a vision for how to optimize the ongoing response to the COVID-19 pandemic for 2022. The presentation focused on:

- the global epidemiological context and factors that continue to drive transmission;
- updates on international traffic as well as COVID-19 proof of vaccination and test result certificates;
- the status of COVID-19 vaccination; and
- the strategic objectives for countries to incorporate in their COVID-19 response.

The Committee discussed key issues including SARS-CoV-2 variants; use and equitable access to antivirals; vaccine protection and global shifts in the supply and demand for COVID-19 vaccines; hybrid immunity; potential future scenarios for SARS-CoV-2 transmission and challenges posed by concurrent health emergencies; and how Member States are responding to the COVID-19 pandemic. **The Committee also noted with concern the growing fatigue among communities worldwide in response to the COVID-19 pandemic and challenges posed by the lack of trust in scientific guidance and governments....**

The Committee unanimously agreed that the COVID-19 pandemic still constitutes an extraordinary event that continues to adversely affect the health of populations around the world, poses an ongoing risk of international spread and interference with international traffic, and requires a coordinated international response. The Committee stressed the importance for States Parties to prepare for future scenarios with the assistance of WHO and to continue robust use of the essential tools (e.g. vaccines, therapeutics, and diagnostics). The Committee concurred that the COVID-19 pandemic remains a PHEIC and offered its advice to the Director-General.

The Director-General determined that the COVID-19 pandemic continues to constitute a PHEIC. He accepted the advice of the Committee and issued the Committee's advice to States Parties as Temporary Recommendations under the IHR.

The Emergency Committee will be reconvened within three months or earlier, at the discretion of the Director-General. The Director-General thanked the Committee for its work.

.....
.....

Equitable access to COVID-19 vaccination is a humanitarian imperative - ICRC

Statement by the International Committee of the Red Cross (ICRC) at the United Nations Security Council, New York 11 April 2022. Delivered by Dr. Esperanza Martinez, Senior Advisor to the Office of the Director-General

12-04-2022 | Statement

Mr. President, Members of the Council, Colleagues,

Thank you for the opportunity to address you today and to the UK for spotlighting the importance of vaccination in conflict settings through Resolution 2565 as well as continuing the Council's focus on what needs to be done.

COVID-19 has killed more than 6 million people globally – with the number probably much higher as these are only the officially reported figures. The successes in the development and production of vaccines mean that many countries are starting to regain a sense of normalcy. However, to end the pandemic, vaccination needs to occur everywhere – and this is not the case in conflict-affected areas.

In conflict-settings, health systems torn apart by conflict are less able to contain the spread of diseases across frontlines and international borders. Vaccination and other health activities in such contexts are incredibly difficult to carry out. Furthermore, many people in conflict settings are overlooked in public health responses, including people displaced, detained, or living in areas controlled by non-state armed groups.

Moreover, in areas affected by armed conflict, COVID-19 is not the most pressing issue people face as the most basic needs – such as food, water, and shelter – are often not covered. Even if the health system continues to function, its focus turns from general health care, including vaccination, to treating war-wounded patients and keeping the core of the system functioning. This can happen in any conflict setting.

Mr. President,

The good news is that, as the supply of vaccine doses grows, the potential to get jabs in arms grows too. **To achieve this in conflict settings, the International Committee of the Red Cross presents three asks to this Council, UN Member States, and conflict-affected countries:**

First, ensure that International Humanitarian Law is respected

Under international humanitarian law, hospitals and other medical facilities as well as medical personnel – including those administering vaccines – are specifically protected from attacks. And where states cannot meet the basic needs of populations, they must allow impartial humanitarian organizations to conduct health activities – including vaccination.

These obligations are reaffirmed in Resolution 2565. We call on all parties to conflict to implement them in good faith as attacks on healthcare have a profound effect on people's lives and future.

Second, integrate COVID-19 vaccinations into a broader health strategy and in tandem strengthen the health system

We have seen vaccines expire on airport tarmacs in Afghanistan, Nigeria, South Sudan, and several other places. Some of these vaccines were wasted because they arrived with too short expiry dates. Others, because the receiving countries' health systems were not ready to distribute them. Countries need a degree of capacity to deliver vaccines.

The COVID-19 pandemic offers an opportune moment to strengthen the health systems in conflict-affected countries. We need to consider how COVID-19 vaccinations can be routinized where possible and integrated with other health services that are prioritized during times of conflict.

This doesn't mean we have to do everything, but we must invest in country preparedness and fortify the building blocks of the health system that support immunizations – and which in turn support the response to other pre-existing health needs. Critically, this investment can help address renewed outbreaks of other highly contagious and lethal diseases – which are occurring today, for example with measles in Afghanistan and polio in the Democratic Republic of Congo.

One strategy to address this is to invest in developing health workers' capacity and skillsets – as well as improving key components of service delivery, such as local supply chains and infrastructure. This is both critical and doable in contexts affected by armed conflict. The ICRC, for example, supported more than 600 health facilities in Iraq in 2021 which allowed the administration of over 14 million doses of COVID-19 vaccines.

Third, involve the community in vaccination activities and adequately resource community-engagement

Done well, effective community engagement is a force multiplier. It enhances the safety of frontline health workers and expands the reach of vaccination and other health efforts. Community involvement allows the community to identify pressing needs, take ownership, and spread the word about health-related programs.

For example, the ICRC established a network of Community Health Committees attached to 28 Primary Health Care Centres in Somalia and 16 in South Sudan. Many representatives are women from the community who can play an important role in the control and prevention of the COVID-19 pandemic and other diseases.

However, done poorly, ineffective or lack of community engagement can undermine public trust in vaccinations and government-run programs more broadly, with ramifications beyond this pandemic. We have witnessed the effects of distrust in West Africa with Ebola and now in many countries with COVID-19. Even if communities can be reached, people will not accept being vaccinated if they do not trust those administering the vaccine, and they do not see other pressing priorities being addressed.

For the ICRC and the wider Red Cross and Red Crescent Movement, community engagement ensures that communities' insights are an integral part of the design and delivery of programs, and that people have accurate information about vaccines and public health interventions, so they can make informed choices for themselves. Beyond vaccination, the ICRC strives to build trust with communities and parties to conflict concerning all its humanitarian activities.

The ICRC – as part of the Red Cross and Red Crescent Movement – will continue to play its part.
The ICRC helped to administer more than 21 million doses of COVID-19 vaccines last year in areas impacted by armed conflict.

And we continue our offer of services to support states to implement their vaccination plans, to support National Red Cross and Red Crescent Societies as humanitarian auxiliaries, and to act as a neutral intermediary to facilitate access to vaccines and vaccination activities in hard-to-reach areas.

Equitable access to COVID-19 vaccination is a humanitarian imperative. Our collective recovery depends on it, because the longer COVID circulates anywhere, the longer it remains a threat everywhere.

.....
.....

UNICEF - COVID Vaccines

"We must take the rapid action needed to accelerate vaccination."

COVID-19 Vaccine Delivery Partnership Global Lead Coordinator Ted Chaiban's remarks at the Security Council briefing on equitable access to COVID-19 vaccines in conflict and humanitarian crises
Remarks 04/12/2022
As prepared.

..."**Just over 1 million cases of COVID-19 were reported to WHO in the last 24 hours - the pandemic is still far from over.** We have safe and available vaccines that can protect against death and severe illness caused by COVID-19 and help avoid the next variant and there is an urgency, with over six million lives having been lost to date, to raise COVID-19 vaccination in countries that did not have this opportunity in 2021. **The next six months are critical.**

**"More than 11.1 billion doses of COVID-19 vaccines have been administered globally:
:: 124 of the 194 WHO member states have vaccinated more than 40% of their population
:: 51 countries have reached more than 70% of their population; only 11% in low-income countries.
:: 83% of the population in WHO's Africa region and 51% in its Eastern Mediterranean region, which includes Afghanistan, remain unvaccinated.**

"In 2022, we must take the rapid action needed to accelerate vaccination. The window of opportunity is gradually closing. We risk losing the momentum and failing on vaccine equity.

"The COVID-19 Vaccine Delivery Partnership is focused, amongst others, on 34 countries which were at 10% or less full vaccine coverage and face the biggest challenges to increasing vaccination coverage. The goal is to vaccinate all adults and adolescents – starting with the elderly, healthcare and other frontline workers and those with underlying health conditions who are at the highest risk from COVID-19.

"19 of the 34 countries identified for concerted support by the Delivery Partnership are included in the Global Humanitarian Overview for 2022.

"We know there are many competing health, humanitarian and economic priorities in these countries. We must therefore **use every opportunity to bundle or integrate COVID-19 vaccination with other health and humanitarian interventions** and leverage these investments for the longer term strengthening of health systems.

"In many countries, COVID-19 vaccination is being integrated with measles campaigns and, in complement, with maternal health and routine immunization. COVID-19 vaccination is being used to strengthen cold chain, health management information systems and to train and provide incentives to health workers, including the surge required.

"With strong political leadership, country coordination and planning, and implementation of mass vaccination campaigns, countries can quickly pick up their vaccination rates and coverage. Since January 2022, the number of countries with a full population vaccination coverage rate at or below 10% has dropped from 34 countries to 18 countries currently...

..."I am speaking to you now from the Democratic Republic of the Congo where this week we will be meeting the government and key partners to better address the urgent bottlenecks to expanding vaccination coverage across this country of nearly 100 million people. We know Risk Communications and Community Engagement is a key component to success so we will be working with in-country

partners to support clear communications to increase demand and work to improve convenient access to vaccination.

"In humanitarian settings, from Afghanistan to Yemen, addressing low vaccination rates requires integrating with humanitarian priorities, working with humanitarian partners and a sustained, country-by-country effort to identify and overcome the primary obstacles to increasing vaccination rates among the populations affected by natural disasters, conflict and socio-political instability.

"We recognize the significance of the Humanitarian Buffer, a mechanism established within the COVAX facility to ensure access to COVID-19 vaccines for high-risk and vulnerable populations living in humanitarian settings. As of today, two applicants have successfully received vaccine doses via the Humanitarian Buffer -- the Ministries of Health in Iran and Uganda -- but the partners are committed to make it a more user friendly, easily accessible mechanism to ensure that humanitarian populations not included in national vaccination plans, microplanning, or the implementation process can equally benefit from vaccination.

"The COVID-19 Vaccine Delivery Partnership and partners -- UNICEF, WHO, GAVI, the World Bank, the Africa CDC and others -- are providing concerted support to all these countries, mobilizing political engagement, providing flexible funding (\$21 million in last two months), strategic advice and technical assistance. We are lining up partners behind one country team, one plan and one budget to put countries at the center and reduce their transaction costs.

"Mr President, Excellencies, to address the significant vaccine equity gap that continues to pose a threat for global health security, please consider the following requests:

"First, continue your strong support and actions to implement Resolutions 2532 and 2565 with a particular focus on ensuring countries continue to prioritise COVID-19 vaccination.

"Second, with appreciation for the US\$4.8 billion in pledges made at the COVAX AMC summit co-hosted with Germany, turn these commitments into support for lower-income countries' COVID-19 vaccination needs, with a priority on delivery systems. Flexible, agile funding is vital and these investments can last beyond the pandemic.

"Third, advocate for and help guarantee full, safe and unhindered access, in line with International Humanitarian Law -- including protecting humanitarian corridors -- as a means to getting vital supplies of vaccines and other essential equipment for the delivery of COVID-19 vaccinations to populations in need and ensure the safety of health and humanitarian personnel administering vaccines in humanitarian settings.

"Fourth, advocate across government, and work with UN country teams and partners to ensure strong national vaccination planning that addresses the needs of all populations living within the national territory, regardless of nationality, migration or refugee status.

"Fifth, engage in the important conversations on the global health emergency architecture and advocate for strong governance and an investment in the basics of primary health care as a key element of future pandemic preparedness."



WHO, WIPO, WTO launch trilateral COVID-19 technical assistance platform

11 April 2022

The World Health Organization (WHO), the World Intellectual Property Organization (WIPO) and the WTO launched on 11 April 2022 their new Trilateral COVID-19 Technical Assistance Platform. This new tool aims to help members and WTO accession candidates address their capacity building needs to respond to the COVID-19 pandemic.

In welcoming the initiative, WTO Director-General Okonjo-Iweala said the Platform “takes our trilateral collaboration to the next level: **a one-stop shop for members to seek and receive support from the three organizations on all available tools including intellectual property flexibilities to improve access to COVID-19 vaccines, medicines, and related technologies.**”

WHO Director-General Tedros Adhanom Ghebreyesus said: “The WHO-WIPO-WTO partnership aims to place public health innovation and intellectual property at the service of access to health technologies for everyone. Countries should consider using this platform and all other available mechanisms to promote public health.”

WIPO Director General Daren Tang noted the three organizations “came together last summer to offer our expertise and resources jointly to help members overcome the complex challenges posed by the pandemic. I am proud that through our partnership, we are providing a Trilateral Technical Assistance Platform that gives members a ‘one-stop shop’ access to the expertise and resources of all three organizations. By working together to support the strengthening of innovation, trade and health, we can help members overcome and recover.”

The new [Platform](#) for COVID-19 related technical assistance provides WTO members and accession candidates an overview of technical assistance activities offered by the three organizations. **It supports members and accession candidates seeking to address their needs for COVID-19 vaccines, medicines and related technologies and facilitates requests for the provision of timely and tailored technical assistance with a view to making full use of all available options...**



COVID-19 vaccines and treatments output continues apace; as health systems and last mile hurdles remain - IFPMA

- **To date, over 13 billion doses of COVID-19 vaccines have been produced and 11 billion have been administered. Presently, vaccine supplies outstrip global demand, with voluntary** technology transfer playing a significant role. Urgent steps are needed to provide a high level of protection against COVID-19 among the elderly and vulnerable populations wherever they live.
- **Several COVID-19 treatments are now standard of care for COVID-19.** Biopharmaceutical companies with approved treatments are scaling up manufacturing capacity with wide use of voluntary licensing, but the effective roll out of treatments to all patients is dependent on swift regulatory approval, allocation strategies, health systems capacity, and testing.

- The historic scaling up of manufacturing and the numerous technology transfers and voluntary licenses are further proof that intellectual property has been an enabler throughout the pandemic. **Recent COVID-19 waves underscore that equitable access to vulnerable populations should be commanding all our collective efforts.**

13 April 2022, Geneva – The COVID-19 pandemic continues to evolve and challenge the public health response. Meanwhile, the biopharmaceutical industry continues to bring its R&D expertise and solutions to the pandemic, while scaling up manufacturing of safe and effective treatments and vaccines. **There is now broad acknowledgement that supplies of COVID-19 vaccines have outstripped demand, and manufacturing of treatments for people who have contracted COVID-19 or who are unable to be vaccinated is on track thanks, in part, to widescale voluntary licensing...**

To date, 13.7 billion COVID-19 vaccine doses have been delivered^[1]. While 11 billion COVID-19 vaccines have been administered thus far, equitable distribution remains a major concern. The spread of the Omicron BA2 variant underscores the importance of targeted immunization and should focus all minds to ensure full course vaccinations are administered with haste to all in need, in particular the elderly, vulnerable populations, and people who are immunosuppressed.

Sufficient vaccines are available to continue inoculation programs, since more than 7.98 billion doses could be produced this year. More than half of the doses forecast to be produced this year will be COVID-19 vaccines produced by companies member of [IFPMA](#), together with partners who are in technology transfer agreements with them. In parallel to COVID-19 vaccine manufacturing, innovation into broader spectrum vaccines to tackle the pandemic continues apace, with combination vaccines or vaccines that are easier to transport and administer.

The biopharmaceutical industry remains steadfast in its position that [steps urgently need to be taken](#) to ensure all healthcare workers, the elderly, and those who are immunosuppressed or vulnerable through comorbidities wherever they live should receive a full course of vaccines. “The trend that we predicted last year that COVID-19 vaccine supplies will outstrip global demand has been proven correct,” said Thomas Cueni, Director General, IFPMA. The COVID-19 vaccine manufacturing scale-up has seen 372 partnerships forged, of which 88% (329) include technology transfer or fill & finish. 51 manufacturing and production agreements were made in developing countries (LICs and LMICs).

In addition, several important commitments have been made by biopharmaceutical companies that are set to change Africa’s vaccine manufacturing landscape in years to come. “To continue to advocate that vaccine equity is caused by scarcity of vaccines due to a lack of technology transfer flies in the face of the facts – both for the numbers of vaccines available but also for the way vaccines are made. The reasons for the woeful inequity are manifold but cannot be laid at the door of intellectual property,” Cueni explained. “We remain steadfast in our verdict that the proposed World Trade Organization’s TRIPS waiver is a solution in search of a problem. It is a distraction and is misleading in its promise of equity for this pandemic. And it sends the wrong signal to innovators for future pandemics,” he concluded...

There is increasing acceptance that society will have to live with COVID-19. The vaccines and treatments that have been developed since the pandemic are essential public health tools to both alleviate the impact of the virus but also help people with other conditions access the care they need.

Continued innovation remains essential. Fortunately, there is a strong pipeline for both COVID-19 vaccines and treatments, building on the 10 vaccines that have so far received WHO EUL approval[2] and the 18 different treatments that have been approved in the UK, USA, and EU.

Further innovation is critical to keep pace with the evolving nature of COVID-19. **Today, there are 271 vaccines in preclinical and 147 in clinical phases and there are 1827 treatment candidates in clinical trials.** Innovation is not without its risks; for example, so far 9 vaccine candidates that reached the final phase of clinical trials have been discontinued and 6 applications were rejected.

[1] <https://www.unicef.org/supply/covid-19-vaccine-market-dashboard>

[2] <https://covid19.trackvaccines.org/agency/who/>

.....
.....

COVAX Guidance, Analysis, Reports

Emergency use of unproven clinical interventions outside clinical trials: ethical considerations - WHO

12 April 2022 :: 60 pages

Overview

This document is intended to provide policy-makers, authorities in charge of the prevention and management of a public health emergency, such as ministries of health, national regulatory authorities and national disaster management agencies, health-care workers, ethics committees and others, with: an updated version of the ethical framework for use of unproven clinical interventions outside clinical trials during public health emergencies (the MEURI ethical framework), general and operational recommendations for implementing the framework and • answers to questions that stakeholders may raise.

Table 2. Outline of WHO’s updated ethical framework for emergency use of unproven clinical interventions outside clinical trials (the MEURI ethical framework)

I. Justification	II. Ethical and regulatory oversight
1. Public health emergency	6. Review and approval by authority and ethics committee
2. Absence of proven intervention	7. Minimization of risks
3. Impossibility of initiating research immediately	8. Responsible transition
4. Scientific support based on a favourable risk–benefit ratio	9. Fair access to scarce unproven interventions
5. Effective use of resources	
III. Consent process	IV. Contribution to evidence
10. Individual informed consent	12. Monitoring, collecting and sharing relevant data
11. Community engagement	

Equitable access to COVID-19 tools - WHO

Aligning the private sector with national response efforts

12 April 2022 :: 28 pages

Overview

COVID-19 has reinforced the need for whole-of-society and whole-of-government approaches to the pandemic response. This has tested the foundation of public and private sector relations in healthcare, and either nurtured or exacerbated trust. In many instances, the private sector has demonstrated solidarity and delivered critical essential and COVID-19-related health services and products. However adverse behaviours have also featured. These have exacerbated the State's duty to 'protect' the right to health, improve health security and system resilience for universal health care. The pandemic has further exposed the need for robust governance of health systems. This is good for both the private and public sectors, but most importantly, consumers, including those most likely to be left behind. This rapid review seeks to understand why and where there has been swift and proactive action to build better governance of national COVID-19 response, to cross-countries lessons sharing on how to govern the private sector in health to maximize the COVID-19 response.

.....
.....
.....

Coronavirus [COVID-19] - WHO

Public Health Emergency of International Concern (PHEIC)

<https://www.who.int/emergencies/diseases/novel-coronavirus-2019>

Weekly Epidemiological and Operational updates

Last update: 14 Apr 2022

Confirmed cases :: 500 186 525

Confirmed deaths :: 6 190 349

Vaccine doses administered: 11 294 502 059

.....

Weekly epidemiological update on COVID-19 - 12 April 2022

Overview


Globally, during the week of 4 through 10 April 2022, the number of new COVID-19 cases has continued to decline for the third consecutive week, with a 24% decrease as compared to the previous week. Also the number of new weekly deaths continue the decreasing trend (-18% as compared to the previous week).

Across the six WHO regions, over 7 million cases and over 22 000 deaths were reported, with all the regions showing decreasing trends both in the number of new weekly cases and new weekly deaths. As of 10 April 2022, over 496 million confirmed cases and over 6 million deaths have been reported globally.

In this edition we provide:

- Special Focus: Update on WHO COVID-19 global rapid risk assessment
- Updates on circulating SARS-CoV-2 variants of concern (VOCs), including information on Omicron descendent lineages.

Figure 1. COVID-19 cases reported weekly by WHO Region, and global deaths, as of 10 April 2022**



.....
.....

Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process 02 April 2022

[New additions; Full scale view available at title link above]

[Updated on 16 Apr 2022]

.....

COVID Vaccines/Therapeutics - Developer/Manufacturer Announcements

[Selected press releases/announcements from organizations from WHO EUL/PQ listing above and other organizations]

AstraZeneca

Press Releases - No new digest announcements identified

Bharat Biotech

Press Releases - No new company announcements identified

BioCubaFarma – Cuba

Últimas Noticias - Website not leading at inquiry

Biological E

News - No new digest announcements identified

Biontech

Press Releases

Pfizer and BioNTech Announce Data Demonstrating High Immune Response Following a Booster Dose of Their COVID-19 Vaccine in Children 5 Through 11 Years of Age

14 April 2022

BioNTech and Matinas BioPharma Announce Exclusive Research Collaboration to Evaluate Novel Delivery Technology for mRNA-based Vaccines

11 April 2022

CanSinoBIO

News - Website not responding at inquiry

CIGB

Latest News - No new digest announcements identified

Cinagen

Recent News - No new digest announcements identified

Clover Biopharmaceuticals - China

News - No new digest announcements identified

Curevac [Bayer Ag – Germany]

News

April 11, 2022

CureVac and GSK Enter into Pandemic Preparedness Contract with German Government

- German government reserves domestic manufacturing capacity until 2029 to ensure rapid access to mRNA vaccines developed by CureVac and GSK
- Five-year contract enables production of up to 80 million vaccine doses at short notice in case of a public health emergency, contributing to increased pandemic preparedness

Gamaleya National Center

Latest News and Events - See Russia below.

IMBCAMS, China

Home - Website not responding at inquiry

Janssen/JNJ

Press Releases - No new digest announcements identified

Medicago

Media - No new digest announcements identified

Moderna

Press Releases

11 April, 2022

Moderna Announces First Participants Dosed in Phase 1/2 Study with mRNA-1020 and mRNA-1030 Seasonal Influenza Vaccine Candidates

Nanogen

News - No new digest announcements identified

Novavax

Press Releases

Apr 13, 2022

[Swissmedic Grants Conditional Marketing Authorization for Novavax COVID-19 Vaccine](#)

Pfizer

Recent Press Releases

04.14.2022

[Pfizer and BioNTech Announce Data Demonstrating High Immune Response Following a Booster Dose of their COVID-19 Vaccine in Children 5 Through 11 Years of Age](#)

R-Pharm

<https://rpharm-us.com/index.php>

[No news or media page identified]

Sanofi Pasteur

Press Releases - No new digest announcements identified

Serum Institute of India

NEWS & ANNOUNCEMENTS - No new digest announcements identified

Shifa Pharmed [Iran]

<http://shafapharmed.com/>

No news page identified.

Sinopharm/WIBPBIBP

News - No new digest announcements identified

Sinovac

Press Releases - No new digest announcements identified

Vector State Research Centre of Virology and Biotechnology

Home - No new digest announcements identified

WestVac Biopharma

Media - No new digest announcements identified

Zhifei Longcom, China

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]

[No website identified]

.....

GSK

Press releases for media - No new digest announcements identified

Merck

News releases

Merck Announces U.S. FDA has Granted Breakthrough Therapy Designation for V116, the Company's Investigational 21-Valent Pneumococcal Conjugate Vaccine, for the Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults

April 14, 2022

Novartis

News - No new digest announcements identified

SK Biosciences

Press releases -

SK bioscience Initiates Clinical Development of Antiviral Nasal Spray for Prevention of COVID-19

- SK began developing an innovative technology to prevent viral infections and relieve symptoms through intranasal spray
- The spray is expected to be used as the first line of defense to prevent virus spread before vaccine development
- The project is being funded by the Bill & Melinda Gates Foundation through a grant to IAVI and a subgrant to SK bioscience

2022.04.13

Valneva

Press Releases

April 14, 2022

Valneva Receives Conditional Marketing Authorization from UK MHRA for its Inactivated COVID-19 Vaccine

.....
.....

UNICEF COVID-19 Vaccine Market Dashboard :: Agreements Table Accessed 16 Apr 2022

An overview of information collected from publicly announced bilateral and multilateral supply agreements [no new agreements since 10/22/2021 reported]



35

vaccines **approved for use** by at least one national regulatory authority ¹



10

vaccines in WHO's **Emergency Use Listing**



17.8bn

doses **secured globally**



\$2 - \$40

reported vaccine **price range** per dose



2.8bn

doses **COVAX** has secured, optioned, or received as donations



1.43bn


doses **shipped through COVAX** to 145 countries

.....
.....

[COVID-19 Global Targets and Progress Tracker](#) - IMF

The COVID-19 Global Targets and Progress Tracker presents a consolidated view of the progress towards global COVID-19 targets, barriers in access to COVID-19 tools, and delivery of donor pledges.

Daily Vaccination Rate Needed to Reach 70% by Mid-2022, assuming 2-dose vaccines (per 100 people)



The global targets presented in the Tracker are based on an alignment of the targets identified in the IMF Pandemic Proposal, ACT-A Strategic Plan & Budget, and the US-hosted Global C19 Summit, and as such have been reaffirmed by multilateral institutions and global leaders. We will continue to enhance the tracker as we improve our data collection efforts.


.....
.....

Global Dashboard on COVID-19 Vaccine Equity

The Dashboard is a joint initiative of UNDP, WHO and the University of Oxford with cooperation across the UN system, anchored in the SDG 3 Global Action Plan for Healthy Lives and Well-being for All.

Dashboard on Vaccine Equity [accessed 16 Apr 2022]: <https://data.undp.org/vaccine-equity/>


See also visualization on [Vaccine Access](#) and [Vaccine Affordability](#)





Global COVID-19 Access Tracker

<https://www.covid19globaltracker.org/>



Duke – Launch and Scale Speedometer

The Race for Global COVID-19 Vaccine Equity

A flurry of nearly 200 COVID-19 vaccine candidates are moving forward through the development and clinical trials processes at unprecedented speed; more than ten candidates are already in Phase 3 large-scale trials and several have received emergency or limited authorization. Our team has aggregated and analyzed publicly available data to track the flow of procurement and manufacturing and better understand global equity challenges. We developed a data framework of relevant variables and conducted desk research of publicly available information to identify COVID vaccine candidates and status, deals and ongoing negotiations for procurement and manufacturing, COVID burden by country, and allocation and distribution plans. We have also conducted interviews with public officials in key countries to better understand the context and challenges facing vaccine allocation and distribution [accessed 24 July 2021]

[See our COVID Vaccine Purchases research](#)

[See our COVID Vaccine Manufacturing research](#)

[See our COVID Vaccine Donations & Exports research](#)



Overview of donations by top 10 donating countries

Bar chart is ordered by total number of doses pledged.

Donut charts are ordered by proportion of pledged donations shipped.

Country Category:

Top 10 Donating Countries



Data updated on Apr 15th 2022

Duke GLOBAL HEALTH
Innovation Center

.....
.....

COVID Vaccines – OCHA:: HDX

[COVID-19 Data Explorer: Global Humanitarian Operations](#)

COVID-19 Vaccine Roll-out

16 Apr 2022 | COVAX (WHO,GAVI,CEPI), UNDESA, Press Reports | [DATA](#)

Global COVID-19 Figures: 500M total confirmed cases; 6.2M total confirmed deaths

Global vaccines administered: 11.4B

Number of Countries: 28

COVAX Allocations Round 4-9 (Number of Doses): 170M

COVAX Delivered (Number of Doses): 280M

Other Delivered (Number of Doses): 260M

Total Delivered (Number of Doses): 540M

Total Administered (Number of Doses): 390M

.....

.....


Multilateral Leaders Task Force on COVID-19 [IMF, World Bank Group, WHO, WTO]

<https://data.covid19taskforce.com/data>

A global effort to help developing countries access and deliver COVID-19 vaccines, testing, and therapeutics, as they work to end the pandemic and boost economic recovery.

The International Monetary Fund, World Bank Group, World Health Organization and World Trade Organization have joined forces to accelerate access to COVID-19 vaccines, therapeutics and diagnostics by leveraging multilateral finance and trade solutions, particularly in low- and middle-income countries.

Website accessed **16 Apr 2022**: <https://data.covid19taskforce.com/data> The global view below is complemented by country-specific dashboards [here](#).



.....
.....

Our World in Data


[Coronavirus \(COVID-19\) Vaccinations](#) [Accessed 16 Apr 2022]

- [65%](#) of the world population has received at least one dose of a COVID-19 vaccine. [11.45 billion doses](#) have been administered globally, and [11.79 million](#) are now administered each day.
- Only [15.2%](#) of people in low-income countries have received at least one dose.

Share of people who completed the initial COVID-19 vaccination protocol, Apr 14, 2022

Our World
in Data

Total number of people who received all doses prescribed by the initial vaccination protocol, divided by the total population of the country.



Source: Official data collated by Our World in Data - Last updated 15 April 2022, 11:00 (London time)

Note: Alternative definitions of a full vaccination, e.g. having been infected with SARS-CoV-2 and having 1 dose of a 2-dose protocol, are ignored to maximize comparability between countries.

OurWorldInData.org/coronavirus • CC BY


Dec 13, 2020 Apr 14, 2022

Share of people who completed the initial COVID-19 vaccination protocol, Apr 14, 2022

Our World
in Data

Total number of people who received all doses prescribed by the initial vaccination protocol, divided by the total population of the country.

+ Add country



Source: Official data collated by Our World in Data - Last updated 15 April 2022, 11:00 (London time)

Note: Alternative definitions of a full vaccination, e.g. having been infected with SARS-CoV-2 and having 1 dose of a 2-dose protocol, are ignored to maximize comparability between countries.

OurWorldInData.org/coronavirus • CC BY

Dec 13, 2020 Apr 14, 2022

.....
.....

U.S.: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

HHS

News

No new digest content identified.

BARDA-ASPR – U.S. Department of HHS [to 16 Apr 2022]

<https://aspr.hhs.gov/newsroom/Pages/NewsRoomHome.aspx>

News

Renewal of the Determination that a Public Health Emergency Exists Nationwide as the Result of the Continued Consequences of Coronavirus Disease 2019 (COVID-19) Pandemic

Tuesday, April 12, 2022

.....

FDA

Press Announcements

FDA Takes Important Steps to Increase Racial and Ethnic Diversity in Clinical Trials

Agency's Focus on Inclusion in Trials for All Medical Products Aligns with Biden Administration's Cancer Moonshot Goal of Addressing Inequities and Beyond

April 13, 2022

Today, the U.S. Food and Drug Administration issued a new draft guidance to industry for developing plans to enroll more participants from underrepresented racial and ethnic populations in the U.S. into clinical trials – expanding on the agency's [previous guidances](#) for industry to improve clinical trial diversity.

"The U.S. population has become increasingly diverse, and ensuring meaningful representation of racial and ethnic minorities in clinical trials for regulated medical products is fundamental to public health," said FDA Commissioner Robert M. Califf, M.D. "Going forward, achieving greater diversity will be a key focus throughout the FDA to facilitate the development of better treatments and better ways to fight diseases that often disproportionately impact diverse communities. This guidance also further demonstrates how we support the Administration's Cancer Moonshot goal of addressing inequities in cancer care, helping to ensure that every community in America has access to cutting-edge cancer diagnostics, therapeutics and clinical trials."

Despite having a disproportionate burden for certain diseases, racial and ethnic minorities are frequently underrepresented in biomedical research. Clinical trials provide a crucial base of evidence for evaluating whether a medical product is safe and effective; therefore, enrollment in clinical trials should reflect the diversity of the population that is ultimately going to use the treatment. It is known that biological differences exist in how people respond to certain therapies. For example, variations in genetic coding can make a treatment more or less toxic for one racial or ethnic group than another.

These variations can also make drugs like antidepressants and blood-pressure medications less effective for certain groups.

This draft guidance, "[Diversity Plans to Improve Enrollment of Participants from Underrepresented Racial and Ethnic Subgroups in Clinical Trials](#)," recommends that sponsors of medical products develop and submit a Race and Ethnicity Diversity Plan to the agency early in clinical development, based on a framework outlined in the guidance...

Regulatory Actions

Vaccines and Related Biological Products Advisory Committee- FDA

<https://www.fda.gov/advisory-committees/blood-vaccines-and-other-biologics/vaccines-and-related-biological-products-advisory-committee>

Calendar

No new calendar dates identified.

.....

White House [U.S.] [to 16 Apr 2022]

Briefing Room – Selected Major COVID Announcements

Press Statement - COVID Context

No new digest content identified.

U.S. Department of State [to 16 Apr 2022]

<https://www.state.gov/coronavirus/releases/>

Press Statement - COVID Context

No new digest content identified.

USAID [to 16 Apr 2022]

<https://www.usaid.gov/news-information/press-releases>

Selected Press Releases, Statements, Announcements

[USAID Announces New Programs to Protect Our Ocean](#)

April 14, 2022

Press Release

The U.S. Agency for International Development (USAID) announced [24 initiatives](#) to protect our ocean at the Our Ocean Conference 2022 in Palau.

[USAID Announces \\$18 Million Contribution to Education Cannot Wait](#)

April 13, 2022

Press Release

The U.S. Agency for International Development (USAID) will contribute an additional \$18 million to Education Cannot Wait (ECW), the major global fund for education in emergencies. USAID announced the additional funding during ECW's scoping visit to Moldova to support the response to the crisis in Ukraine.

[USAID and LIXIL Announce \\$10 Million to Confront the Global Sanitation Crisis](#)

April 12, 2022

Today, the U.S. Agency for International Development and LIXIL, a global housing and sanitation products multinational company, launched the Partnership for Better Living to expand access to affordable sanitation and hygiene solutions for the underserved in up to 11 countries across sub-Saharan Africa and Asia by 2026.

.....
.....

Europe: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

European Medicines Agency

[News & Press Releases](#)

Press Releases

[No new digest content identified]

.....


European Centre for Disease Prevention and Control

<https://www.ecdc.europa.eu/en>

Latest Updates [Selected]

[No new digest content identified]

.....



Accessed 16 Apr 2022

<https://vaccinetracker.ecdc.europa.eu/public/extensions/COVID-19/vaccine-tracker.html#uptake-tab>

.....

European Commission

<https://ec.europa.eu/commission/presscorner/home/en>

Latest [Selected]

Press release 14 April 2022

Green Deal: EU announces €1 billion worth of commitments to protect the ocean

Today, at the Our Ocean Conference (OOC) in Palau, the EU has renewed its pledges towards international Ocean governance.

Press release 12 April 2022

Ukraine: EU humanitarian operation in the Republic of Moldova enhances assistance for refugees

Since the start of Russia's invasion on 24 February, the refugee influx of civilians fleeing Ukraine to reach neighbouring countries has resulted in skyrocketing humanitarian needs.

Press release 9 April 2022


Stand Up For Ukraine: €9.1 billion pledged in support of internally displaced and refugees

The "Stand Up for Ukraine" global pledging event and campaign has raised €9.1 billion for people fleeing the Russian invasion, inside Ukraine and abroad, including €1 billion from the European Commission.

.....
.....

Africa: COVID-19 – Announcements/Regulatory Actions/Deployment

<https://africacdc.org/covid-19-vaccination/>



Vaccines received from COVAX

51

Countries

Vaccines received bilaterally

52

Countries

Vaccines received from AVATT

38

Countries

.....
.....

Russia: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Russia: Sputnik V – "the first registered COVID-19 vaccine"

<https://sputnikvaccine.com/newsroom/pressreleases/>

Press Releases

Latest Updates [Selected]

[No new digest content identified]

.....
.....

India: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Ministry of Health and Family Welfare

<https://www.mohfw.gov.in/>

COVID-19 INDIA as on :
16 April 2022, 08:00 IST
(GMT+5:30)

(↑↓ Status change since
yesterday)

Active (0.03%)

11366 (175↑)

Discharged (98.76%)

42507834 (796↑)

Deaths (1.21%)

521747 (4↑)

COVID-19 Vaccination
as on : 16 April 2022,
08:00 IST (GMT+5:30)

Total Vaccination : 1,86,38,31,723 (6,89,724↑)

Government of India – Press Information Bureau

Latest Press Releases

COVID - 19 Vaccination Update - Day 456

:: India's cumulative vaccination coverage crosses 186.49 Crore

:: More than 11 lakh Vaccine doses administered today till 7 pm

:: More than 2.42 Crore Vaccine Doses administered to 12-14 age group so far

Posted On: 16 APR 2022 8:05PM by PIB Delhi

Indian Council for Medical Research (ICMR)

<https://www.icmr.gov.in/media.html>

Press Releases

No new digest content identified.

.....
.....

China: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

[We did not identify official announcements about Shanghai confirming the reports below; See China CDC below for additional announcements]

China tightens controls as Shanghai reports record Covid cases

Japan urges local government to address business concerns as ongoing restrictions hit commerce

Reuters in Shanghai

Sat 16 Apr 2022 10.42 EDT

Shanghai reported a record number of symptomatic Covid-19 cases on Saturday and other areas across [China](#) tightened controls as the country kept up its “dynamic clearance” approach that aims to stamp out the highly transmissible Omicron variant.

The Zhengzhou airport economic zone, a central Chinese manufacturing area that includes Apple supplier Foxconn, announced a 14-day lockdown on Friday “to be adjusted according to the epidemic situation”...

...Shanghai itself, which is at the centre of China’s recent Covid surge starting in early March, reported a record 3,590 symptomatic cases for 15 April, as well as 19,923 asymptomatic cases. The asymptomatic case number was up slightly from 19,872 cases a day earlier.

The city’s case tally makes up the vast majority of cases nationwide even as most of its 25 million residents remain under lockdown...

At the Zhengzhou economic zone, only personnel with valid passes, health codes and proof of negative Covid tests would be able to leave during the two-week period, although “special vehicles” would be able to travel normally for work reasons, local authorities said in a post on an official WeChat instant messaging account.

Overall, China reported 24,791 new coronavirus cases on 15 April, of which 3,896 were symptomatic and 20,895 were asymptomatic, the National Health Commission said on Saturday.

.....
.....

UN OCHA – Current Emergencies

Current Corporate Emergencies

Afghanistan

No new updates identified.

Northern Ethiopia

Ethiopia - Northern Ethiopia Humanitarian Update Situation Report, 14 Apr 2022

HIGHLIGHTS

- Humanitarian partners have not been able to move any additional aid supplies into Tigray by road since the convoy entered on 1 and 2 April.
- About 36 metric tons of HIV medical supplies were airlifted to Mekelle, the first time since July 2021. It will be enough to provide treatment for 46,000 patients for six months.

- Authorities in Amhara relocated more than 20,000 people out of the planned 70,000 people in North Wello and Wag Hamra zones to new designated sites since mid-March.
- WFP assisted over 35,000 people with food in Gulina, Barahle and Dalole woredas in Afar during the reporting period, reaching over 235,000 people since last week of February.
- More than 11,000 children under five and pregnant and lactating women received supplementary nutrients in Wag Harma and North Wello zones in Amhara between 1 and 10 April.

Ukraine

Ukraine: Humanitarian Impact Situation Report (As of 12:00 p.m. (EET) on 15 April 2022)

.....

WHO & Regional Offices [to 16 Apr 2022]

<https://www.who.int/news>

News [Selected]

14 April 2022

Departmental news

The Global Diabetes Compact: a promising first year

14 April 2022

Departmental news

World Chagas Disease Day: finding and reporting every case

13 April 2022

Statement

Statement on the eleventh meeting of the International Health Regulations (2005)

Emergency Committee regarding the coronavirus disease (COVID-19) pandemic

[See Milestones above for detail]

13 April 2022

Departmental news

Ukraine next country to receive technology from the WHO mRNA technology transfer hub

12 April 2022

Departmental news

Meeting of WHO Director-General's Expert Group on Cervical Cancer Elimination, 19 April 2022

11 April 2022

Departmental news

SAGE April 2022 meeting highlights

[See Milestones above for detail]

11 April 2022

Departmental news

WHO, WIPO, WTO launch trilateral COVID-19 technical assistance platform

11 April 2022

News release

[One-dose Human Papillomavirus \(HPV\) vaccine offers solid protection against cervical cancer](#)

[See Milestones above for detail]

.....

WHO Director General Speeches [selected]

<https://www.who.int/director-general/speeches>

Selected

14 April 2022

Speech

[WHO Director-General's opening remarks on Member State Information Session on COVID-19](#) - 14 April 2022

14 April 2022

Speech

[WHO Director-General's opening remarks at the Briefing to the African Union Ambassadors in Geneva on Strengthening Local Manufacturing Capacity](#) – 14 April 2022

13 April 2022

Speech

[WHO Director-General's opening remarks at the WHO press conference](#) – 13 April 2022

12 April 2022

Speech

[WHO Director-General's opening remarks at the International Strategic Dialogue on Noncommunicable Diseases and the Sustainable Development Goals](#) – 12 April 2022

12 April 2022

Speech

[WHO Director-General's opening remarks at the Global Launch of the WHO QualityRights e-training to advance mental health, eliminate stigma and promote community inclusion](#) –

12 April 2022

12 April 2022

Speech

[WHO Director-General's opening remarks at the Public Hearing regarding a new international instrument on pandemic preparedness and response](#) – 12 April 2022

.....

WHO Regional Offices

Selected Press Releases, Announcements

[WHO African Region](#)

:: [Africa witnesses longest-running decline in COVID-19 cases](#) 14 April 2022

Brazzaville – Africa is experiencing its longest-running decline in COVID-19 infections since the onset of the pandemic. Recorded weekly cases have fallen for the past 16 weeks, while deaths have dropped for the last eight.

Infections—largely due to the Omicron-driven fourth pandemic wave—have tanked from a peak of over 308 000 cases weekly at the start of the year to less than 20 000 in the week ending on 10 April 2022. Over the past week, around 18 000 cases and 239 deaths were recorded, a decline of 29% and 37% respectively compared with the week before. This low level of infection has not been seen since April 2020 in the early stages of the pandemic in Africa...

:: [Botswana, South Africa deepen probe into new Omicron sub-variants](#) 12 April 2022

Brazzaville – Researchers in Botswana and South Africa have detected new sub-lineages of the Omicron variant of the SARS-CoV-2 and are carrying out further investigations to fully understand crucial traits such as infectivity and virulence.

The identified sub-lineages variant are BA.4 and BA.5. World Health Organization (WHO) experts are working with scientists and researchers in the two countries to deepen analysis of the sub-lineages which have so far been identified in four people in Botswana and 23 in South Africa. Outside Africa, the BA.4 and the BA.5 have been confirmed in Belgium, Denmark, Germany and the United Kingdom...

:: [Deaths from noncommunicable diseases on the rise in Africa](#) 11 April 2022

Accra/Brazzaville – Noncommunicable diseases such as cancer, cardiovascular diseases and diabetes are increasingly becoming the main cause of mortality in sub-Saharan Africa, where the diseases were responsible for 37% of deaths in 2019, rising from 24% in 2000 largely due to weaknesses in the implementation of critical control measures including prevention, diagnosis and care. This comes on the eve of a high-level heads of state and health leaders meeting in Ghana to find ways of accelerating progress against noncommunicable diseases...

WHO Region of the Americas PAHO

:: 13 Apr 2022

[Less than 10% of those infected with Chagas disease receive timely diagnosis and treatment](#)

PAHO calls for detection of all cases and equitable access to care for this disease, which causes about 30,000 new infections each year. Washington, DC, April 13, 2022 (PAHO)- Due to its silent nature, less than 10% of those infected with Chagas disease each year receive timely diagnosis and, therefore, effective treatment in Mexico, Central...

:: 11 Apr 2022

[One-dose Human Papillomavirus \(HPV\) vaccine offers solid protection against cervical cancer](#)

Geneva, 11 April 2022 (WHO)- The 4-7 April convening of the WHO Strategic Advisory Group of Experts on Immunization (SAGE) evaluated the evidence that has been emerging over past years that single-dose schedules provide comparable efficacy to the two or three-dose regimens. SAGE's review concluded that a single-dose Human Papillomavirus (HPV)...

WHO South-East Asia Region SEARO

No new digest content identified.

WHO European Region EURO

:: [Regional Director pledges WHO support to help Ukraine's health system build back better during visit to Lviv](#) 13-04-2022

:: [Adjusting health financing for people fleeing conflict: WHO releases new guidance for countries in Europe](#) 13-04-2022

:: ['Ensuring high-quality of HIV Care for displaced people from Ukraine'](#) 13-04-2022

:: [Novo Nordisk Foundation supports WHO's emergency response in Ukraine and neighbouring countries with 25 million Danish kroner/3.4 million euros](#) 13-04-2022

WHO Eastern Mediterranean Region EMRO

:: [Taking the battle against malaria to its source – the mosquito](#) 14 April 2022

:: [WHO and Ksrelief join efforts in the fight against child malnutrition in Yemen](#) 13 April 2022

:: [WHO delivers rapid antigen tests for COVID-19 to Iraq](#) 11 April 2022

WHO Western Pacific Region

No new digest content identified.

.....

Disease Outbreak News (DONs)

Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.

[15 April 2022 | Circulating vaccine-derived poliovirus type 3 – Israel](#)

[15 April 2022 | Acute hepatitis of unknown aetiology – the United Kingdom of Great Britain and Northern Ireland](#)

.....

WHO Events

<https://www.who.int/news-room/events/1>

[Selected]

[WHO Public Health Laboratories knowledge sharing webinars - Genomic surveillance and building up Next Generation Sequencing capacity](#)

20 April 2022 11:00 – 12:30 CET

World Immunization Week

World Immunization Week 2022 - Long Life for All

24 – 30 April 2022

[World Malaria Day 2022 - Harness innovation to reduce the malaria disease burden and save lives](#)

25 April 2022

10th ACT-Accelerator Facilitation Council meeting

26 April 2022 12:30 – 15:00 CET

.....

New WHO Publications

<https://www.who.int/publications/i>

Selected Titles

14 April 2022

Environmental surveillance for SARS-COV-2 to complement public health surveillance – Interim Guidance

Overview

Routine diagnostic surveillance for COVID-19 has been augmented with environmental surveillance (ES) in wastewater in many locations. ES provides additional evidence on virus in circulation at population level including presence or absence, early warning of increasing or decreasing trends, and information on variants of concern or interest.

This guidance provides advice on:

- What situations ES has been shown to add value to public health decision making
- What is needed to plan and coordinate an effective ES programme
- How to carry out data collection, analysis, interpretation and communication of results.

This guidance is targeted at public health officials who want to understand and integrate complementary ES into COVID-19 control strategies.

14 April 2022

Emergency in Ukraine: external situation report #7, published 14 April 2022: reporting period: 7–13 April...

13 April 2022

INSPIRE: seven strategies for ending violence against children: uptake between 2016 and 2021

13 April 2022

Health system performance assessment

12 April 2022

Optimized broth microdilution plate methodology for drug susceptibility testing of Mycobacterium tuberculosis...

12 April 2022

WHO Expert Committee on Biological Standardization: seventy-fourth report

12 April 2022

Emergency use of unproven clinical interventions outside clinical trials: ethical considerations

[See COVID above for detail]

12 April 2022

Ethics and medical radiological imaging: a policy brief for health-care providers

12 April 2022

Towards better engagement of the private sector in health service delivery

12 April 2022

Equitable access to COVID-19 tools

[See COVID above for detail]

11 April 2022

[How to temperature map cold chain equipment and storage areas](#)

11 April 2022

[Noncommunicable Diseases Progress Monitor 2022](#)

.....
.....
.....

CDC/ACIP [U.S.] [to 16 Apr 2022]

<http://www.cdc.gov/media/index.html>

<https://www.cdc.gov/vaccines/acip/index.html>

Tuesday, April 12, 2022

[CDC Media Telebriefing: 2020 STD Surveillance Report](#)

.....

[ACIP Meetings](#)

Next ACIP Meeting

April 20, 2022 11:00am – 4:00pm ET.

This meeting is virtual. No registration is required to watch the webcasts.

[Webcast Link](#)

No Agenda posted at inquiry

.....

MMWR Weekly: Current Volume (71) April 15, 2022 / No. 15

[PDF of this issue](#)

- Surveillance to Track Progress Toward Polio Eradication — Worldwide, 2020–2021
- COVID-19 Mortality and Vaccine Coverage — Hong Kong Special Administrative Region, China, January 6, 2022–March 21, 2022
- Effectiveness of COVID-19 mRNA Vaccination in Preventing COVID-19–Associated Hospitalization Among Adults with Previous SARS-CoV-2 Infection — United States, June 2021–February 2022

.....

[Coronavirus Disease 2019 \(COVID-19\)- CDC](#)

Approximately 25 announcements/reports/data summaries.

:: 4/15/22 Overall US COVID-19 Vaccine Distribution and Administration Update as of Fri, 15 Apr 2022 06:00:00 EST

:: 4/15/22 Recommendations for Tribal Ceremonies and Gatherings During the COVID-19 Outbreak

.....
.....

Africa CDC [to 16 Apr 2022]

<http://www.africacdc.org/>

News

No new digest content identified.

.....
.....

China CDC

<http://www.chinacdc.cn/en/>

National Health Commission of the People's Republic of China [to 16 Apr 2022]

<http://en.nhc.gov.cn/>

News

April 16: Daily briefing on novel coronavirus cases in China

On April 15, 31 provincial-level regions and the Xinjiang Production and Construction Corps on the Chinese mainland reported 3,896 new cases of confirmed infections.

National Medical Products Administration – PRC [to 16 Apr 2022]

<http://english.nmpa.gov.cn/>

News

Chinese mainland reports 3,472 new local COVID-19 cases, 3,200 in Shanghai

2022-04-15

The Chinese mainland Thursday reported 3,472 locally-transmitted confirmed COVID-19 cases, of which 3,200 were in Shanghai, according to the National Health Commission (NHC)'s report Friday.

Over 3.3b COVID-19 vaccine doses administered on Chinese mainland

2022-04-13

Over 3.3 billion COVID-19 vaccine doses had been administered on the Chinese mainland as of April 11, data from the National Health Commission showed on April 12.

CCDC Weekly Reports: Current Volume (4)

022-04-15 / No. 15 NATIONAL ANTI-CANCER WEEK ISSUE

[View PDF of this issue](#)

Foreword: Cancer Prevention and Early Action

Preplanned Studies: Burden of Disease Due to Cancer — China, 2000–2019

Preplanned Studies: Economic Burden of Malignant Tumors — Yichang City, Hubei Province, China, 2019

Vital Surveillances: Cancer Mortality and Cause Eliminated Life Expectancy in Key Areas of Four Provinces — China, 2008–2018

Perspectives: Colorectal Cancer Screening in China: Status, Challenges, and Prospects — China, 2022

.....

Contents [*click to move among sections*]

:: [Coronavirus \[COVID-19\] - WHO](#)

:: [Error! Reference source not found.](#):: [Organization Announcements](#)

:: [Journal Watch](#)

.....

Organization Announcements

Editor's Note:

Careful readers will note that the number and range of organizations now monitored in our *Announcements* section below has grown as the impacts of the pandemic have spread across global economies, supply chains and programmatic activity of multilateral agencies and INGOs.

Airfinity [to 16 Apr 2022]

<https://www.airfinity.com/insights>

INSIGHTS & COMPANY NEWS

[Airfinity downgrades its global COVID-19 vaccine revenue forecast to \\$64.1B](#)

Published by Airfinity

Apr 10, 2022

Airfinity has downgraded its global sales forecast for COVID-19 vaccines this year from \$80.8bn to \$64.1bn.

Paul G. Allen Frontiers Group [to 16 Apr 2022]

<https://alleninstitute.org/news-press/>

News

No new digest content identified.

BMGF - Gates Foundation [to 16 Apr 2022]

<https://www.gatesfoundation.org/ideas/media-center>

Press Releases and Statements

No new digest content identified.

Bill & Melinda Gates Medical Research Institute [to 16 Apr 2022]

<https://www.gatesmri.org/news>

The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people

No new digest content identified.

CARB-X [to 16 Apr 2022]

<https://carb-x.org/>

News

No new digest content identified.

Center for Vaccine Ethics and Policy – GE2P2 Global Foundation [to 16 Apr 2022]

<https://centerforvaccineethicsandpolicy.net/>

News/Analysis/Statements

:: Past weekly editions and posting of all segments of ***Vaccines and Global Health: The Week in Review*** are available here.

:: **[Informed Consent: A Monthly Review – April 2022](#)** is now posted here

:: **[Statement on ICF \[Informed Consent Form\] Posting for Clinical Trials Involving Gene Editing/Gene Therapies - Invitation to Endorse](#)**

:: **[Patients, Politics, Pressure :: Pharma Stays Steady \[Mostly\] In Russia Sanctions Context Observations at 30 March 2022](#)** David R Curry

CEPI – Coalition for Epidemic Preparedness Innovations [to 16 Apr 2022]

<http://cepi.net/>

Latest News

No new digest content identified.

DARPA – Defense Advanced Research Projects Agency [U.S.] [to 16 Apr 2022]

<https://www.darpa.mil/news>

News

No new digest content identified.

Duke Global Health Innovation Center [to 16 Apr 2022]

<https://dukeghic.org/>

Our Blog

No new digest content identified.

EDCTP [to 16 Apr 2022]

<http://www.edctp.org/>

The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials

News

No new digest content identified.

Emory Vaccine Center [to 16 Apr 2022]

<http://www.vaccines.emory.edu/>

Vaccine Center News

No new digest content identified.

European Vaccine Initiative [to 16 Apr 2022]

<http://www.euvaccine.eu/>

Latest News, Events

No new digest content identified.

Evidence Aid [to 16 Apr 2022]

Evidence Aid aims to save lives and livelihoods in disasters by providing decision-makers with the best available evidence and by championing its use.

<http://www.evidenceaid.org/>

New Resources

No new digest content identified.

Fondation Merieux [to 16 Apr 2022]

<http://www.fondation-merieux.org/>

News, Events

Mérieux Foundation & University of Geneva co-organized event

22nd Advanced Vaccinology Course (ADVAC)

May 9 - 20, 2022 - Les Pensières Center for Global Health, Veyrier-du-Lac (France)

Gavi [to 16 Apr 2022]

<https://www.gavi.org/>

News Releases

No new digest content identified.

GHIT Fund [to 16 Apr 2022]

<https://www.ghitfund.org/newsroom/press>

Press Releases

No new digest content identified.

Global Fund [to 16 Apr 2022]

<https://www.theglobalfund.org/en/news/>

News & Stories

No new digest content identified.

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [to 16 Apr 2022]

<https://www.glopid-r.org/news/>

News

No new digest content identified

Hilleman Laboratories [to 16 Apr 2022]

<http://www.hilleman-labs.org/>

News & Insights

No new digest content identified

HHMI - Howard Hughes Medical Institute [to 16 Apr 2022]

<https://www.hhmi.org/news>

Press Room

No new digest content identified.

Human Vaccines Project [to 16 Apr 2022]

<http://www.humanvaccinesproject.org/>

News

No new digest content identified.

IAVI [to 16 Apr 2022]

<https://www.iavi.org/>

Latest News

No new digest content identified.

ICRC [to 16 Apr 2022]

<https://www.icrc.org/en/whats-new>

What's New [Selected]

[Equitable access to COVID-19 vaccination is a humanitarian imperative](#)

Statement by the International Committee of the Red Cross (ICRC) at the United Nations Security Council, New York 11 April 2022. Delivered by Dr. Esperanza Martinez, Senior Advisor to the Office of the Director-General.

12-04-2022 | Statement

[See COVID above for detail]

International Coalition of Medicines Regulatory Authorities [ICMRA]

<http://www.icmra.info/drupal/en/news>

Selected Statements, Press Releases, Research

No new digest content identified.

IFFIm

<http://www.iffim.org/>

Press Releases/Announcements

No new digest content identified.

IFRC [to 16 Apr 2022]

<http://media.ifrc.org/ifrc/news/press-releases/>

Press Releases [Selected]

14/04/2022

[Tonga: Red Cross tackles triple disaster - COVID-19, volcanic fallout, tsunami](#)

14/04/2022

[IFRC to support more than 2 million people affected by the conflict in Ukraine with its largest ever](#)

Institut Pasteur [to 16 Apr 2022]

<https://www.pasteur.fr/en/press-area>

Press Documents

Press release 14.04.2022

[Decoding a direct dialog between the gut microbiota and the brain](#)

Gut microbiota by-products circulate in the bloodstream, regulating host physiological processes including immunity,...

Press release 13.04.2022

[Colon cancer: how mutation of the APC gene disrupts lymphocyte migration](#)

In patients with familial adenomatous polyposis, a genetic disease predisposing to colon cancer, mutations of the APC...

Press release 12.04.2022

[HIV: The Antibodies of "Post-treatment Controllers"](#)

A very small percentage of people with HIV-1, known as "post-treatment controllers" (PTCs), are able to control their...

IOM / International Organization for Migration [to 16 Apr 2022]

<http://www.iom.int/press-room/press-releases>

News - Selected

No new digest content identified.

ISC / International Science Council [to 16 Apr 2022]

<https://council.science/current/>

ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.

News Blogs Podcasts Events

Blogs

[A call to ISC Members: how to assist displaced Ukrainian scholars](#)

11.04.2022

IVAC [to 16 Apr 2022]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

Updates; Events

[World Immunization Week 2022: Webinars](#)

April 2022

During World Immunization Week 2022 the International Vaccine Access Center, along with global immunization and indigenous health partners, will host a three webinars. Registration is free, and we encourage all to sign up and save these dates on their calendars. Enabling Equitable Access to COVID-19 Vaccines for Indigenous Populations When: April 26, 2022 from 6:00 [...]

IVI [to 16 Apr 2022]

<http://www.ivi.int/>

IVI News & Announcements

No new digest content identified.

Johns Hopkins Center for Health Security [to 16 Apr 2022]

<https://www.centerforhealthsecurity.org/news/center-news/>

Center News

No new digest content identified.

MSF/Médecins Sans Frontières [to 16 Apr 2022]

<http://www.msf.org/>

Latest [Selected Announcements]

War in Ukraine

[Finding our most useful role in our response in and around Ukraine](#)

Project Update 11 Apr 2022

National Academy of Medicine - USA [to 16 Apr 2022]

<https://nam.edu/programs/>

News

No new digest content identified.

National Academy of Sciences - USA [to 16 Apr 2022]

<http://www.nasonline.org/news-and-multimedia/>

News

No new digest content identified.

National Vaccine Program Office - U.S. HHS [to 16 Apr 2022]

<https://www.hhs.gov/vaccines/about/index.html>

Upcoming Meetings/Latest Updates

No new digest content identified.

NIH [to 16 Apr 2022]

<http://www.nih.gov/>

News Releases

[Website not responding at inquiry]

OECD [to 16 Apr 2022]

<http://www.oecd.org/newsroom/publicationsdocuments/bydate/>

Newsroom/Library

COVID-19 assistance to developing countries lifts foreign aid in 2021 - OECD

Foreign aid from official donors rose to an all-time high of USD 179 billion in 2021, up 4.4% in real terms from 2020 as developed countries stepped up their help for developing countries grappling with the COVID-19 crisis, according to preliminary data collected by the OECD.

PATH [to 16 Apr 2022]

<https://www.path.org/media-center/>

Press Releases

No new digest content identified.

Sabin Vaccine Institute [to 16 Apr 2022]

<http://www.sabin.org/updates/pressreleases>

Statements and Press Releases

No new digest content identified.

UNAIDS [to 16 Apr 2022]

<http://www.unaids.org/en>

Selected Press Releases/Reports/Statements

14 April 2022

Life-saving logistics in Ukraine

UNHCR Office of the United Nations High Commissioner for Refugees [to 16 Apr 2022]

<http://www.unhcr.org/en-us/media-centre.html>

Selected News Releases, Announcements

UN Refugee Agency opposes UK plan to export asylum

14 Apr 2022

Spiraling costs, surging conflict, and soaring climate disasters create a desperate future for millions of refugees across Eastern Africa

WFP and UNHCR Joint News Release

13 Apr 2022

Statement on risks of trafficking and exploitation facing refugees from Ukraine attributed to UNHCR's Assistant High Commissioner for Protection

The following statement is attributed to Gillian Triggs, UNHCR's Assistant High Commissioner for Protection

12 Apr 2022

UNICEF [to 16 Apr 2022]

<https://www.unicef.org/media/press-releases>

Press Releases, News Notes, Statements [Selected]

Remarks

04/12/2022

"We must take the rapid action needed to accelerate vaccination."

<https://www.unicef.org/press-releases/we-must-take-rapid-action-needed-accelerate-vaccination>

[See COVID above for detail]

Unitaid [to 16 Apr 2022]

<https://unitaid.org/>

Featured News

13 April 2022

World Chagas Day: Unitaid remains committed to improving access to testing and treatment to reduce mother-to-child transmission of Chagas

... Unitaid's efforts, underway in Brazil, Bolivia, Colombia and Paraguay, seek to demonstrate new approaches to testing, treatment and care for Chagas disease that will generate valuable evidence to facilitate the adoption of feasible and cost-effective health strategies for combatting Chagas disease across the region and globally...

Vaccine Equity Cooperative [nee Initiative] [to 16 Apr 2022]

<https://vaccineequitycooperative.org/news/>

News

No new digest content identified.

Vaccination Acceptance & Demand Initiative [Sabin] [to 16 Apr 2022]

<https://www.vaccineacceptance.org/>

Announcements, Blog

No new digest content identified.

Vaccine Confidence Project [to 16 Apr 2022]

<http://www.vaccineconfidence.org/>

News, Research and Reports

No new digest content identified.

Vaccine Education Center – Children's Hospital of Philadelphia [to 16 Apr 2022]

<http://www.chop.edu/centers-programs/vaccine-education-center>

News

No new digest content identified.

Wellcome Trust [to 16 Apr 2022]

<https://wellcome.ac.uk/news>
News. Opinion, Reports
No new digest content identified.

The Wistar Institute [to 16 Apr 2022]
<https://www.wistar.org/news/press-releases>
Press Releases
No new digest content identified.

WFPHA: World Federation of Public Health Associations [to 16 Apr 2022]
<https://www.wfpha.org/>
Latest News - Blog
No new digest content identified.

World Bank [to 16 Apr 2022]
<http://www.worldbank.org/en/news/all>
Selected News, Announcements
[Green Fiscal Reforms can Protect Vulnerable Households and Boost COVID-19 Recovery Efforts in Europe](#)
BRUSSELS, April 14, 2022 - Green fiscal reforms can help protect vulnerable households and support pandemic recovery efforts in European countries on the road to climate neutrality by 2050, says a new...
Date: April 14, 2022 Type: Press Release

[Joint Statement: The Heads of the World Bank Group, IMF, WFP, and WTO Call for Urgent Coordinated Action on Food Security](#)
Proposed actions to help vulnerable countries include providing emergency food supplies and deploying financial support to households and countries; facilitating unhindered trade; investing in sustainable...
Date: April 13, 2022 Type: Press Release

[Joint Statement: The Heads of the World Bank Group, IMF, WFP, and WTO Call for Urgent Coordinated Action on Food Security](#)
Proposed actions to help vulnerable countries include providing emergency food supplies and deploying financial support to households and countries; facilitating unhindered trade; investing in sustainable...
Date: April 13, 2022 Type: Statement

World Customs Organization – WCO [to 16 Apr 2022]
<http://www.wcoomd.org/>
Latest News
No new digest content identified.

World Organisation for Animal Health (OIE) [to 16 Apr 2022]

<https://www.oie.int/en/media/news/>

Press Releases, Statements

No new digest content identified.

WTO - World Trade Organisation [to 16 Apr 2022]

http://www.wto.org/english/news_e/news_e.htm

WTO News and Events [Selected]

World Bank, IMF, WFP and WTO call for urgent coordinated action on food security

13 April 2022

The heads of the World Bank, the International Monetary Fund (IMF), the United Nations World Food Program (WFP) and the WTO issued a joint statement on 13 April urging coordinated action to help vulnerable countries address growing threats to food security. The proposed actions include providing emergency food supplies and deploying financial support to households and countries, facilitating unhindered trade, and investing in sustainable food production and nutrition security.

WHO, WIPO, WTO launch trilateral COVID-19 technical assistance platform

11 April 2022

The World Health Organization (WHO), the World Intellectual Property Organization (WIPO) and the WTO launched on 11 April 2022 their new Trilateral COVID-19 Technical Assistance Platform. This new tool aims to help members and WTO accession candidates address their capacity building needs to respond to the COVID-19 pandemic.

[See COVID above for detail]

.....

ARM [Alliance for Regenerative Medicine] [to 16 Apr 2022]

<https://alliancerm.org/press-releases/>

Selected Press Releases

No new digest content identified.

BIO [to 16 Apr 2022]

<https://www.bio.org/press-releases>

Press Releases, Letters, Testimony, Comments [Selected]

No new digest content identified.

DCVMN – Developing Country Vaccine Manufacturers Network [to 16 Apr 2022]

<http://www.dcvmn.org/>

News; Upcoming events

No new digest content identified.

ICBA – International Council of Biotechnology Associations [to 16 Apr 2022]

<https://internationalbiotech.org/news/>

News

No new digest content identified.

IFPMA [to 16 Apr 2022]

<http://www.ifpma.org/resources/news-releases/>

Selected Press Releases, Statements, Publications

COVID-19 vaccines and treatments output continues apace; as health systems and last mile hurdles remain

13 April 2022

[See COVID above for detail]

IFPMA statement at public hearings regarding a new international instrument on pandemic preparedness and response

13 April 2022

The biopharmaceutical industry is committed to working with stakeholders to improve pandemic preparedness for the future and to ensure equitable access to medical countermeasures.

Any system should be built on what worked well during the COVID-19 pandemic with robust IP frameworks enabling collaborations, as well as immediate sharing of pathogens.

As the INB enters deeper discussions on a new instrument we believe these should be informed by a few core principles:

1. The negotiation process should be inclusive and transparent, involving private sector and all critical contributors to PPR efforts
2. In the spirit of subsidiarity, tasks and decision-making processes which are more efficiently performed nationally or regionally should remain at these levels.
3. We call for clarity on roles and expectations, improving forecast and reducing unnecessary red tape
4. Any new system should be complementary to existing instruments and include clarifications on how it relates to other existing frameworks
5. Any system should allow for immediate open access of pathogens and genetic sequence data and correct the negative effects of access and benefit-sharing legislation.
6. **Promote equitable access to diagnostics, treatments and vaccines based on medical need, enhancing solidarity and facilitating emergency financing to institutions procuring for developing countries like COVAX.**
7. Supply chains should be protected from arbitrary export restrictions and other trade barriers
8. The system should build on the private sector's strengths for R&D, manufacturing and distribution, and overall support innovation

International Generic and Biosimilar Medicines Association [IGBA]

<https://www.igbamedicines.org/>

News

No new digest content identified.

International Alliance of Patients' Organizations – IAPO [to 16 Apr 2022]

<https://www.iapo.org.uk/news/topic/6>

Press and media [Selected]

No new digest content identified.

PhRMA [to 16 Apr 2022]
<http://www.phrma.org/>
Latest News [Selected]
No new digest content identified.

* * * *

Contents [click to move among sections]

:: *Coronavirus [COVID-19] - WHO*

:: *Error! **Reference source not found.** :: *Organization Announcements**

:: *Journal Watch*

* * * *

Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics

Volume 13, 2022 Issue 1

<https://www.tandfonline.com/toc/uabr21/current>

[Reviewed earlier]

AMA Journal of Ethics

Volume 24, Number 4: E249-341 Apr 2022

<https://journalofethics.ama-assn.org/issue/health-equity-us-latinx-communities>

Health Equity in US Latinx Communities

Latinx communities in the US include over 60 million people with a plurality of political beliefs, cultural practices, and wealth. This diversity is also expressed in population health data: some health indicators suggest advantages of Latinx community membership while other data demonstrate inequitable disease burden and maldistribution of environmental and occupational risk. Legacies of colonial conquest of the Americas persist in discrimination and marginalization today and are embodied by members of our Latinx communities.

American Journal of Infection Control

April 2022 Volume 50 Issue 4 p367-476

<http://www.ajicjournal.org/current>

[Reviewed earlier]

American Journal of Preventive Medicine

April 2022 Volume 62 Issue 4 p473-660

<https://www.ajpmonline.org/current>

[Reviewed earlier]

American Journal of Public Health

April 2022 112(52)

<http://ajph.aphapublications.org/toc/ajph/current>

Supplement 2 2022 = Global Opioid Crisis

American Journal of Tropical Medicine and Hygiene

Volume 106 (2022): Issue 2 (Feb 2022)

<https://www.ajtmh.org/view/journals/tpmd/106/2/tpmd.106.issue-2.xml>

[Reviewed earlier]

Annals of Internal Medicine

March 2022 Volume 175, Issue 3

<http://annals.org/aim/issue>

[Reviewed earlier]

Artificial Intelligence – An International Journal

Volume 305 April 2022

<https://www.sciencedirect.com/journal/artificial-intelligence/vol/305/suppl/C>

[Reviewed earlier]

BMC Cost Effectiveness and Resource Allocation

<http://resource-allocation.biomedcentral.com/>

(Accessed 16 Apr 2022)

[No new digest content identified]

BMJ Global Health

April 2022 - Volume 7 - 4

<https://gh.bmj.com/content/7/4>

[Reviewed earlier]

BMC Health Services Research

<http://www.biomedcentral.com/bmchealthservres/content>

(Accessed 16 Apr 2022)

Studying SARS-CoV-2 vaccine hesitancy among health professionals in Tunisia

People's lives were seriously affected by the emergence and the spread of the COVID-19 disease. Several vaccines were developed in record time to overcome this pandemic. However, putting an end to this public ...

Authors: Nawel Zammit, Amani El Gueder, Aïcha Brahem, Imen Ayouni, Rim Ghammam, Sihem Ben Fredj, Chaima Sridi, Asma Chouchene, Houda Kalboussi, Olfa El Maalel, Souhaeil Chatti, Jihene Maatoug, Hassen Ghannem and Néjib Mrizak

Citation: BMC Health Services Research 2022 22:489

Content type: Research Published on: 12 April 2022

BMC Infectious Diseases

<http://www.biomedcentral.com/bmcinfectdis/content>

(Accessed 16 Apr 2022)

Children with SARS-CoV-2 infection during the novel coronaviral disease (COVID-19) outbreak in Iran: an alarming concern for severity and mortality of the disease

The rapid worldwide spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections led to public health crises globally and the number of pediatric patients with Coronavirus Disease 2019 (CO...

Authors: Setareh Mamishi, Babak Pourakbari, Mehrzad Mehdizadeh, Amene Navaeian, Hamid Eshaghi, Bahareh Yaghmaei, Reihaneh Hosseinpour Sadeghi, Shiva Poormohammadi, Yasmine Mahmoudieh and Shima Mahmoudi

Citation: BMC Infectious Diseases 2022 22:382

Content type: Research article Published on: 15 April 2022

Determinants of measles vaccination dropout among 12 – 23 months aged children in pastoralist community of Afar, Ethiopia

Measles is a viral disease and a leading vaccine-preventable childhood killer. More than 95% of measles deaths occur in countries with low incomes and weak health infrastructures. In response to this, Ethiopia...

Authors: Chekole Hailu, Girmatsion Fisseha and Aregawi Gebreyesus

Citation: BMC Infectious Diseases 2022 22:376

Content type: Research article Published on: 14 April 2022

BMC Medical Ethics

<http://www.biomedcentral.com/bmcmedethics/content>

(Accessed 16 Apr 2022)

[No new digest content identified]

BMC Medicine

<http://www.biomedcentral.com/bmcmed/content>

(Accessed 16 Apr 2022)

[No new digest content identified]

BMC Pregnancy and Childbirth

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 16 Apr 2022)

[No new digest content identified]

BMC Public Health

<http://bmcpublichealth.biomedcentral.com/articles>

(Accessed 16 Apr 2022)

Barriers to and strategies to address COVID-19 testing hesitancy: a rapid scoping review

Testing is a foundational component of any COVID-19 management strategy; however, emerging evidence suggests that barriers and hesitancy to COVID-19 testing may affect uptake or participation and often these a...

Authors: Mark Embrett, S. Meaghan Sim, Hilary A. T. Caldwell, Leah Boulos, Ziwa Yu, Gina Agarwal, Rhiannon Cooper, Allyson J. Gallant AJ, Iwona A. Bielska, Jawad Chishtie, Kathryn Stone, Janet Curran and Andrea Tricco

Citation: BMC Public Health 2022 22:750

Content type: Research Published on: 14 April 2022

Considering social inequalities in health in large-scale testing for COVID-19 in Montréal: a qualitative case study

Evidence continues to demonstrate that certain marginalised populations are disproportionately affected by COVID-19. While many studies document the impacts of COVID-19 on social inequalities in health, none h...

Authors: Marie-Catherine Gagnon-Dufresne, Lara Gautier, Camille Beaujoin, Ashley Savard Lamothe, Rachel Mikanagu, Patrick Cloos, Valéry Ridde and Kate Zinszer

Citation: BMC Public Health 2022 22:749

Content type: Research Published on: 14 April 2022

Prioritizing COVID-19 vaccination efforts and dose allocation within Madagascar

While mass COVID-19 vaccination programs are underway in high-income countries, limited availability of doses has resulted in few vaccines administered in low and middle income countries (LMICs). The COVID-19 ...

Authors: Fidisoa Rasambainarivo, Tanjona Ramiadantsoa, Antso Raheinandrasana, Santatra Randrianarisoa, Benjamin L. Rice, Michelle V. Evans, Benjamin Roche, Fidiniaina Mamy Randriatsarafara, Amy Wesolowski and Jessica C. Metcalf

Citation: BMC Public Health 2022 22:724

Content type: Research Published on: 12 April 2022

BMC Research Notes

<http://www.biomedcentral.com/bmcresearchnotes/content>

(Accessed 16 Apr 2022)

A network of change: united action on research integrity

Authors: Thomas Rhys Evans, Madeleine Pownall, Elizabeth Collins, Emma L. Henderson, Jade S. Pickering, Aoife O'Mahony, Mirela Zaneva, Matt Jaquiere and Tsvetomira Dumbalska

Citation: BMC Research Notes 2022 15:141

Content type: Commentary Published on: 14 April 2022

Abstract

The last decade has seen renewed concern within the scientific community over the reproducibility and transparency of research findings. This paper outlines some of the various responsibilities of stakeholders in addressing the systemic issues that contribute to this concern. In particular, this paper asserts that a united, joined-up approach is needed, in which all stakeholders, including researchers, universities, funders, publishers, and governments, work together to set standards of research integrity and engender scientific progress and innovation. Using two developments as examples: the adoption of Registered Reports as a discrete initiative, and the use of open data as an ongoing norm change, we discuss the importance of collaboration across stakeholders.

BMJ Evidence-Based Medicine

April 2022 - Volume 27 - 2

<https://ebm.bmj.com/content/27/2>

[Reviewed earlier]

BMJ Open

April 2022 - Volume 12 - 4

<https://bmjopen.bmj.com/content/12/4>

[Reviewed earlier]

Bulletin of the World Health Organization

Volume 100(4); 2022 Apr 1

<https://www.ncbi.nlm.nih.gov/pmc/issues/404046/>

[Reviewed earlier]

Cell

Apr 14, 2022 Volume 185 Issue 8 p1261-1444

<https://www.cell.com/cell/current>

Conversations

[Learning lessons from lipids to make COVID-19 vaccines](#)

A game-changing intervention in the COVID-19 pandemic has been the rapid implementation of highly effective vaccines against SARS-CoV-2. The 2022 Canada Gairdner International Award recognizes Pieter Cullis, Katalin Karikó, and Drew Weissman “for their pioneering work developing nucleoside-modified mRNA and lipid nanoparticle (LNP) drug delivery: the foundational technologies for the highly effective COVID-19 mRNA vaccines.” Cell editor Cheri Sirois caught up with Pieter to discuss how a long interest in basic and applied questions in lipid biology led to this fortuitous collaboration. Excerpts of the conversation are presented below.

Voices

[The voices of Ukrainian and Russian scientists](#)

Rostyslav Stoika, Nikita Gudimchuk, Halyna R. Shcherbata, Andrey Zarausky, Oleksandr Shcheglovitov, Yevgenia Kozorovitskiy, Viktor Korolchuk

The brutal attack on Ukraine by the Russian Federation has shocked the world. While the world works to end the violence and help refugees, as a scientific journal, our thoughts are also with those in the scientific community who are directly or indirectly impacted by the war. We have been inspired by and applaud the labs around the world that have opened their doors to displaced scientists and remain committed to supporting scientists, whoever and wherever they are. Because science requires collaboration and trust, we urge the scientific community to continue efforts like this and to remain united, especially in times as difficult as these. In this Voices piece, we feature short comments from scientists from Ukraine and scientists from Russia. This small sampling is far from exhaustive, but our sincere thanks go to those scientists who were willing to share their thoughts on this volatile and emotionally charged situation; the views expressed are those of the contributors alone. We join the world in hoping for a swift resolution to the conflict, for the good of humanity.

Child Care, Health and Development

Volume 48, Issue 3 Pages: 359-511 May 2022

<https://onlinelibrary.wiley.com/toc/13652214/current>

[Reviewed earlier]

Clinical Pharmacology & Therapeutics

Volume 111, Issue 4 Pages: 705-971 April 2022

<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>

Therapeutic Innovations in Neuroscience

The theme of this issue of *Clinical Pharmacology & Therapeutics* (CPT) encompasses neuroscience in the broad sense to include neurology and psychiatry, nonclinical and clinical aspects, novel clinical trial methodologies, and modeling and simulation approaches applicable to central nervous system (CNS) drug development and therapy. While naturally the last two years have been dominated by coronavirus disease 2019 (COVID-19), it is important not to forget that drug development for other indications has not been stopped, albeit many trials were affected in terms of delays in recruitment and collection of clinical data.

Clinical Therapeutics

February 2022 Volume 44 Issue 2 p155-348

<http://www.clinicaltherapeutics.com/current>

[Reviewed earlier]

Clinical Trials

Volume 19 Issue 1, February 2022

<https://journals.sagepub.com/toc/ctja/19/1>

[Reviewed earlier]

Conflict and Health

<http://www.conflictandhealth.com/>

[Accessed 16 Apr 2022]

[No new digest content identified]

Contemporary Clinical Trials

Volume 114 March 2022

<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/114/suppl/C>

[Reviewed earlier]

The CRISPR Journal

Volume 5, Issue 1 / February 2022

<https://www.liebertpub.com/toc/crispr/5/1>

[Reviewed earlier]

Current Genetic Medicine Reports

Volume 9, issue 4, December 2021

<https://link.springer.com/journal/40142/volumes-and-issues/9-4>

[Reviewed earlier]

Current Opinion in Infectious Diseases

April 2022 - Volume 35 - Issue 2

<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>

[Reviewed earlier]

Current Protocols in Human Genetics

Volume 108, Issue 1 December 2020

<https://currentprotocols.onlinelibrary.wiley.com/toc/19348258/current>

[Reviewed earlier]

Developing World Bioethics

Volume 22, Issue 1 Pages: 1-62 March 2022

<https://onlinelibrary.wiley.com/toc/14718847/current>

[Reviewed earlier]

Development in Practice

Volume 32, Issue 1, 2022

<http://www.tandfonline.com/toc/cdip20/current>

[Reviewed earlier]

Disaster Medicine and Public Health Preparedness

Volume 15 - Issue 6 - December 2021

<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>

[Reviewed earlier]

Disasters

Volume 46, Issue 2 Pages: 299-586 April 2022

<https://onlinelibrary.wiley.com/toc/14677717/current>

[Reviewed earlier]

EMBO Reports

Volume 23 Issue 4 5 April 2022

<https://www.embopress.org/toc/14693178/current>

[Reviewed earlier]

Emerging Infectious Diseases

Volume 28, Number 4—April 2022

<http://wwwnc.cdc.gov/eid/>

[Reviewed earlier]

Epidemics

Volume 38 March 2022

<https://www.sciencedirect.com/journal/epidemics/vol/38/suppl/C>

[Reviewed earlier]

Epidemiology and Infection

Volume 150 - 2022

<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>

[Reviewed earlier]

Ethics & Human Research

Volume 44, Issue 2 Pages: 1-40 March–April 2022

<https://onlinelibrary.wiley.com/toc/25782363/current>

Consent and decisional capacity; Outside experts and IRBs; Therapeutic misconception

[Reviewed earlier]

Ethics & International Affairs

Winter 2021 (35.4) | December 2021

<https://www.ethicsandinternationalaffairs.org/2021/winter-2021-35-4/>

TABLE OF CONTENTS

[Reviewed earlier]

Ethics, Medicine and Public Health

Volume 21 (April 2022)

<https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/21/suppl/C>

[New issue; No digest content identified]

The European Journal of Public Health

Volume 32, Issue 2, April 2022

<https://academic.oup.com/eurpub/issue/32/2>

[Reviewed earlier]

Expert Review of Vaccines

Vol 21 (4) 2022

<https://www.tandfonline.com/toc/ierv20/current>

[Reviewed earlier]

Forum for Development Studies

Volume 49, 2022 - Issue 1

<http://www.tandfonline.com/toc/sfds20/current>

[Reviewed earlier]

Genome Medicine

<https://genomemedicine.biomedcentral.com/articles>

[Accessed 16 Apr 2022]

[No new digest content identified]

Global Health Action

Volume 15, Issue 1 (2022)

<https://www.tandfonline.com/toc/zgha20/current?nav=tocList>

[Reviewed earlier]

Global Health: Science and Practice (GHSP)

Vol. 10, No. 1 February 28, 2022

<http://www.ghspjournal.org/content/current>

[Reviewed earlier]

Global Legal Monitor – Library of Congress/USA

<https://www.loc.gov/collections/global-legal-monitor/>

[Accessed 16 Apr 2022]

[No new digest content identified]

Global Public Health

Volume 17, Issue 4 (2022)
<http://www.tandfonline.com/toc/rgph20/current>
[Reviewed earlier]

Globalization and Health

<http://www.globalizationandhealth.com/>
[Accessed 16 Apr 2022]

What is the impact of intellectual property rules on access to medicines? A systematic review

It is widely accepted that intellectual property legal requirements such as patents and data exclusivity can affect access to medicines, but to date there has not been a comprehensive review of the empirical e...

Authors: Brigitte Tenni, Hazel V. J. Moir, Belinda Townsend, Burcu Kilic, Anne-Maree Farrell, Tessa Keegel and Deborah Gleeson

Citation: Globalization and Health 2022 18:40

Content type: Review Published on: 15 April 2022

Health and Human Rights

Volume 23, Issue 2, December 2021

<https://www.hhrjournal.org/volume-23-issue-2-december-2021/>
[Reviewed earlier]

Health Economics, Policy and Law

Volume 17 - Issue 2 - April 2022

<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>
[Reviewed earlier]

Health Policy and Planning

Volume 37, Issue 3, March 2022

<https://academic.oup.com/heapol/issue/37/3>
[Reviewed earlier]

Health Research Policy and Systems

<http://www.health-policy-systems.com/content>
[Accessed 16 Apr 2022]
[No new digest content identified]

Human Gene Therapy

Volume 33, Issue 5-6 / March 2022

<https://www.liebertpub.com/toc/hum/33/5-6>
[Reviewed earlier]

Humanitarian Practice Network

<https://odihpn.org/>

Online Article

[No new digest content identified]

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)

Volume 18, Issue 1, 2022

<https://www.tandfonline.com/toc/khvi20/current>

[Reviewed earlier]

Immunity

Apr 12, 2022 Volume 55 Issue 4 p575-734

<https://www.cell.com/immunity/current>

[New issue; No digest content identified]

Infectious Agents and Cancer

<http://www.infectagentscancer.com/>

[Accessed 16 Apr 2022]

[No new digest content identified]

Infectious Diseases of Poverty

<http://www.idpjournals.com/content>

[Accessed 16 Apr 2022]

[No new digest content identified]

International Health

Volume 14, Issue 2, March 2022

<https://academic.oup.com/inthealth/issue/14/2>

[Reviewed earlier]

International Human Rights Law Review

Volume 10 (2021): Issue 2 (Dec 2021)

<https://brill.com/view/journals/hrlr/10/2/hrlr.10.issue-2.xml>

[Reviewed earlier]

International Journal of Community Medicine and Public Health

Vol 9, No 1 (2022) January 2022

<https://www.ijcmph.com/index.php/ijcmph/issue/view/84>

[Reviewed earlier]

International Journal of Epidemiology

Volume 51, Issue 1, February 2022

<https://academic.oup.com/ije/issue>

[Reviewed earlier]

International Journal of Human Rights in Healthcare

Volume 14 Issue 5 2021

<https://www.emerald.com/insight/publication/issn/2056-4902/vol/14/iss/5>

Table of Contents

[Reviewed earlier]

JAMA

Apr 12, 2022 Volume 55 Issue 4 p575-734

<https://jamanetwork.com/journals/jama/currentissue>

[New issue; No digest content identified]

JAMA Network

[COVID-19 Update April 16, 2022](#)

These articles on COVID-19 were published across the JAMA Network in the last week.

JAMA Pediatrics

April 2022, Vol 176, No. 4, Pages 335-428

<https://jamanetwork.com/journals/jamapediatrics/currentissue>

[Reviewed earlier]

JB1 Evidence Synthesis

March 2022 - Volume 20 - Issue 3

<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>

[Reviewed earlier]

Journal of Adolescent Health

April 2022 Volume 70 Issue 4 p517-696

<https://www.jahonline.org/current>

[Reviewed earlier]

Journal of Artificial Intelligence Research

Vol. 73 (2022)

<https://www.jair.org/index.php/jair>

[Reviewed earlier]

Journal of Community Health

Volume 47, issue 2, April 2022

<https://link.springer.com/journal/10900/volumes-and-issues/47-2>

[Reviewed earlier]

Journal of Development Economics

Volume 156 May 2022

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/156/suppl/C>

[Reviewed earlier]

Journal of Empirical Research on Human Research Ethics

Volume 17 Issue 1-2, February-April 2022

<http://journals.sagepub.com/toc/jre/current>

[Reviewed earlier]

Journal of Epidemiology & Community Health

April 2022 - Volume 76 - 4

<https://jech.bmj.com/content/76/4>

Commentary

[**Assessment of the proposed intellectual property waiver as a mechanism to address the COVID-19 vaccine scarcity problem**](#) (9 February, 2022)

Julia Barnes-Weise, Ana Santos Rutschman, Reid Adler

Journal of Evidence-Based Medicine

Volume 15, Issue 1 Pages: 1-72 March 2022

<https://onlinelibrary.wiley.com/toc/17565391/current>

ARTICLES

[**An overview of methodological approaches in systematic reviews**](#)

Prabhakar Veginadu, Hanny Calache, Mark Gussy, Akshaya Pandian, Mohd Masood

Pages: 39-54

First Published: 13 April 2022

Journal of Global Ethics

Volume 17, Issue 3, 2021

<http://www.tandfonline.com/toc/rjge20/current>

[Reviewed earlier]

Journal of Health Care for the Poor and Underserved (JHCPU)

Volume 33, Number 1, February 2022

<https://muse.jhu.edu/issue/47329>

Table of Contents

[Reviewed earlier]

Journal of Immigrant and Minority Health

Volume 24, issue 2, April 2022

<https://link.springer.com/journal/10903/volumes-and-issues/24-2>

[Reviewed earlier]

Journal of Immigrant & Refugee Studies

Volume 20, 2022 _ Issue 1

<https://www.tandfonline.com/toc/wimm20/current>

[Reviewed earlier]

Journal of Infectious Diseases

Volume 225, Issue 4, 15 February 2022

<https://academic.oup.com/jid/issue/225/4>

REVIEW

Waning Immunity After Receipt of Pertussis, Diphtheria, Tetanus, and Polio-Related Vaccines: A Systematic Review and Meta-analysis[Get access](#)

Huizhi Gao, Eric H Y Lau, Benjamin J Cowling

The Journal of Infectious Diseases, Volume 225, Issue 4, 15 February 2022, Pages 557–566,

<https://doi.org/10.1093/infdis/jiab480>

Our results supported the notion that secondary vaccine failure may be the reason for reemergence of pertussis and diphtheria. Tetanus and polio vaccines provided more sustained protection.

MAJOR ARTICLES AND BRIEF REPORTS

COVID-19 Vaccination Rates in a Global HIV Cohort

Evelynne S Fulda, Kathleen V Fitch, Edgar T Overton, Markella V Zanni, Judith A Aberg ...

The Journal of Infectious Diseases, Volume 225, Issue 4, 15 February 2022, Pages 603–607,

<https://doi.org/10.1093/infdis/jiab575>

Journal of Medical Ethics

April 2022 - Volume 48 - 4

<http://jme.bmj.com/content/current>

[Reviewed earlier]

Journal of Patient-Centered Research and Reviews

Volume 9, Issue 1 (2022)

<https://institutionalrepository.aah.org/jpcrr/>

[Reviewed earlier]

Journal of Pediatrics

April 2022 Volume 243 p1-246

<http://www.jpeds.com/current>

[Reviewed earlier]

Journal of Pharmaceutical Policy and Practice

<https://joppp.biomedcentral.com/>

[Accessed 16 Apr 2022]

[No new digest content identified]

Journal of Public Health Management & Practice

May/June 2022 - Volume 28 - Issue 3

<https://journals.lww.com/jphmp/pages/currenttoc.aspx>

[New issue; No digest content identified]

Journal of Public Health Policy

Volume 43, issue 1, March 2022

<https://link.springer.com/journal/41271/volumes-and-issues/43-1>

[Reviewed earlier]

Journal of Refugee & Global Health

Volume 4, Issue 1 (2021)

<https://ir.library.louisville.edu/rgh/>

[Reviewed earlier]

Journal of the Royal Society – Interface

April 2022 Volume 19 Issue 189

<https://royalsocietypublishing.org/toc/rsif/current>

[New issue; No digest content identified]

Journal of Travel Medicine

Volume 29, Issue 2, March 2022

<https://academic.oup.com/jtm/issue>

[Reviewed earlier]

Journal of Virology

Volume 96 Number 4 February 2022

<http://jvi.asm.org/content/current>

[Reviewed earlier]

The Lancet

Apr 16, 2022 Volume 399 Number 10334 p1441-1572, e37

<https://www.thelancet.com/journals/lancet/issue/current>

Comment

Understanding of COVID-19 from infection–fatality ratio

Xiaoying Gu, Bin Cao

Understanding of COVID-19 from infection–fatality ratio

Xiaoying Gu, Bin Cao

Articles

Variation in the COVID-19 infection–fatality ratio by age, time, and geography during the pre-vaccine era: a systematic analysis

COVID-19 Forecasting Team

Open Access

Pandemic preparedness and COVID-19: an exploratory analysis of infection and fatality rates, and contextual factors associated with preparedness in 177 countries, from Jan 1, 2020, to Sept 30, 2021

COVID-19 National Preparedness Collaborators

Open Access

Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21

COVID-19 Excess Mortality Collaborators

Open Access

The Lancet Child & Adolescent Health

Apr 2022 Volume 6 Number 4 p215-278, e13-e15

<https://www.thelancet.com/journals/lanchi/issue/current>

[Reviewed earlier]

Lancet Digital Health

Apr 2022 Volume 4 Number 4 e207-e289

<https://www.thelancet.com/journals/landig/issue/current>

[Reviewed earlier]

Lancet Global Health

Apr 2022 Volume 10 Number 4 e448-e584

<https://www.thelancet.com/journals/langlo/issue/current>

[Reviewed earlier]

Lancet Infectious Diseases

Apr 2022 Volume 22 Number 4p 427-562, e101-e127

<https://www.thelancet.com/journals/laninf/issue/current>

[Reviewed earlier]

Lancet Public Health

Apr 2022 Volume 7 Number 4 e291-e390

<https://www.thelancet.com/journals/lanpub/issue/current>

[Reviewed earlier]

Lancet Respiratory Medicine

Apr 2022 Volume 10 Number 4 p313-420, e34-e43

<https://www.thelancet.com/journals/lanres/issue/current>

[Reviewed earlier]

Maternal and Child Health Journal

Volume 26, issue 3, March 2022

<https://link.springer.com/journal/10995/volumes-and-issues/26-3>

[Reviewed earlier]

Medical Decision Making (MDM)

Volume 42 Issue 3, April 2022

<http://mdm.sagepub.com/content/current>

[New issue; No digest content identified]

The Milbank Quarterly

A Multidisciplinary Journal of Population Health and Health Policy

Volume 100, Issue 1 Pages: 1-313 March 2022

<https://onlinelibrary.wiley.com/toc/14680009/current>

[New issue; No digest content identified]

Nature

Volume 604 Issue 7905, 14 April 2022

<https://www.nature.com/nature/volumes/604/issues/7905>

Analysis | 06 April 2022 | Open Access

[A joint NCBI and EMBL-EBI transcript set for clinical genomics and research](#)

Matched Annotation from NCBI and EMBL-EBI (MANE) delivers joint transcript sets from Ensembl/GENCODE and RefSeq for standardizing variant reporting in clinical genomics and research.
Joannella Morales, Shashikant Pujar, Terence D. Murphy

Nature Biotechnology

Volume 40 Issue 4, April 2022

<https://www.nature.com/nbt/volumes/40/issues/4>

Editorial | 04 April 2022

[Licensing for profit *and* for good](#)

The Broad Institute's enlightened licensing approach to CRISPR–Cas9 intellectual property stands out in the otherwise regrettable spat for patent rights over the foundational technology.

Nature Communications

<https://www.nature.com/subjects/health-sciences/ncomms>

(Accessed 16 Apr 2022)

[No new digest content identified]

Nature Genetics

Volume 54 Issue 4, April 2022

<https://www.nature.com/ng/volumes/54/issues/4>

Article | 11 April 2022

[Expanded COVID-19 phenotype definitions reveal distinct patterns of genetic association and protective effects](#)

GWASs based on self-reported phenotypes in 736,723 individuals show distinct associations between risk loci and eight COVID-19 outcomes, suggesting differences in genetic susceptibility to infection upon exposure and severe and symptomatic disease.

Genevieve H. L. Roberts, Raghavendran Partha, Kristin A. Rand

Analysis | 28 March 2022 | Open Access

[Global landscape of SARS-CoV-2 genomic surveillance and data sharing](#)

Analyses on the global diversity of SARS-CoV-2 genomic surveillance across 118 countries and the extent of public availability of genomic data provide evidence to better inform SARS-CoV-2 surveillance policy.

Zhiyuan Chen, Andrew S. Azman, Hongjie Yu

Nature Human Behaviour

Volume 6 Issue 3, March 2022

<https://www.nature.com/nathumbehav/volumes/6/issues/3>

[Reviewed earlier]

Nature Medicine

Volume 28 Issue 3, March 2022

<https://www.nature.com/nm/volumes/28/issues/3>

[Reviewed earlier]

Nature Reviews Genetics

Volume 23 Issue 4, April 2022

<https://www.nature.com/nrg/volumes/23/issues/4>

[Reviewed earlier]

Nature Reviews Immunology

Volume 22 Issue 4, April 2022
<https://www.nature.com/nri/volumes/22/issues/4>
[Reviewed earlier]

Nature Reviews Drug Discovery

Volume 21 Issue 4, April 2022
<https://www.nature.com/nrd/volumes/21/issues/4>
[Reviewed earlier]

New England Journal of Medicine

April 14, 2022 Vol. 386 No. 15
<https://www.nejm.org/toc/nejm/medical-journal>
Perspective
[From Resentment to Reconnection — Reflections on Caring for the Unvaccinated](#)
A.C. Garfinkel

njp Vaccines

<https://www.nature.com/npjvaccines/>
[Accessed 16 Apr 2022]
Article
[No new digest content identified]

Pediatrics

Volume 149, Issue 4, April 1, 2022
<https://pediatrics.aappublications.org/>
[Reviewed earlier]

PharmacoEconomics

Volume 40, issue 3, March 2022
<https://link.springer.com/journal/40273/volumes-and-issues/40-3>
[Reviewed earlier]

PLoS Biology

<https://journals.plos.org/plosbiology/>
(Accessed 16 Apr 2022)
[Biosecurity in an age of open science](#)
James Andrew Smith, Jonas B. Sandbrink
Essay | published 14 Apr 2022 PLOS Biology
<https://doi.org/10.1371/journal.pbio.3001600>
Abstract

The risk of accidental or deliberate misuse of biological research is increasing as biotechnology advances. As open science becomes widespread, we must consider its impact on those risks and

develop solutions that ensure security while facilitating scientific progress. Here, we examine the interaction between open science practices and biosecurity and biosafety to identify risks and opportunities for risk mitigation. Increasing the availability of computational tools, datasets, and protocols could increase risks from research with misuse potential. For instance, in the context of viral engineering, open code, data, and materials may increase the risk of release of enhanced pathogens. For this dangerous subset of research, both open science and biosecurity goals may be achieved by using access-controlled repositories or application programming interfaces. While preprints accelerate dissemination of findings, their increased use could challenge strategies for risk mitigation at the publication stage. This highlights the importance of oversight earlier in the research lifecycle. Preregistration of research, a practice promoted by the open science community, provides an opportunity for achieving biosecurity risk assessment at the conception of research. Open science and biosecurity experts have an important role to play in enabling responsible research with maximal societal benefit.

PLoS Genetics

<https://journals.plos.org/plosgenetics/>

(Accessed 16 Apr 2022)

[No new digest content identified]

PLoS Medicine

<http://www.plosmedicine.org/>

(Accessed 16 Apr 2022)

[No new digest content identified]

PLoS Neglected Tropical Diseases

<http://www.plosntds.org/>

(Accessed 16 Apr 2022)

[No new digest content identified]

PLoS One

<http://www.plosone.org/>

[Accessed 16 Apr 2022]

Research Article

[A scholarly network of AI research with an information science focus: Global North and Global South perspectives](#)

Kai-Yu Tang, Chun-Hua Hsiao, Gwo-Jen Hwang

Research Article | published 15 Apr 2022 PLOS ONE

<https://doi.org/10.1371/journal.pone.0266565>

PLoS Pathogens

<http://journals.plos.org/plospathogens/>

[Accessed 16 Apr 2022]

[No new digest content identified]

PNAS - Proceedings of the National Academy of Sciences of the United States

April 5, 2022 vol. 119 no. 14

<https://www.pnas.org/toc/pnas/119/14>

[New issue; No digest content identified]

Prehospital & Disaster Medicine

Volume 37 - Issue 2 - April 2022

<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>

[Reviewed earlier]

Preventive Medicine

Volume 157 April 2022

<https://www.sciencedirect.com/journal/preventive-medicine/vol/157/suppl/C>

[Reviewed earlier]

Proceedings of the Royal Society B

13 April 2022 Volume 289 Issue 1972

<https://royalsocietypublishing.org/toc/rspb/current>

[Reviewed earlier]

Public Health

Volume 205 Pages e1-e30, 1-216 (April 2022)

<https://www.sciencedirect.com/journal/public-health/vol/205/suppl/C>

[Reviewed earlier]

Public Health Ethics

Volume 14, Issue 3, November 2021

<http://phe.oxfordjournals.org/content/current>

[Reviewed earlier]

Public Health Reports

Volume 137 Issue 2, March/April 2022

<https://journals.sagepub.com/toc/phrg/137/2>

[Reviewed earlier]

Qualitative Health Research

Volume 32 Issue 4, March 2022

<https://journals.sagepub.com/toc/qhra/current>

[Reviewed earlier]

Research Ethics

Volume 18 Issue 2, April 2022

<http://journals.sagepub.com/toc/reab/current>

[Reviewed earlier]

Reproductive Health

<http://www.reproductive-health-journal.com/content>

[Accessed 16 Apr 2022]

[No new digest content identified]

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)

<https://www.paho.org/journal/en>

Selected Articles

[**Realistic evaluation mechanisms in primary health care interventions in rural and marginal urban populations**](#)

Review | Spanish |

13 Apr 2022

[**Geospatial models for SARS-CoV-2 outbreak control in Cartagena and Barranquilla, Colombia, 2020**](#)

Original research | Spanish |

13 Apr 2022

[**Scientific publication speed and retractions of COVID-19 pandemic original articles**](#)

Original research | English |

13 Apr 2022

[**Management and impact of interventions to reduce COVID-19 cases in Costa Rica**](#)

Original research | Spanish |

13 Apr 2022

Risk Analysis

Volume 42, Issue 3 Pages: 429-655 March 2022

<https://onlinelibrary.wiley.com/toc/15396924/current>

[New issue; No digest content identified]

Risk Management and Healthcare Policy

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>

[Accessed 16 Apr 2022]

Original Research

Acceptance of COVID-19 Vaccine Among High-Risk Occupations in a Port City of China and Multifaceted Strategies for Increasing Vaccination Coverage: A Cross-Sectional Study

Sun Y, Li B, Li N, Li B, Chen P, Hao F, Sun C

Risk Management and Healthcare Policy 2022, 15:643-655

Published Date: 14 April 2022

Science

Volume 376| Issue 6590| 15 Apr 2022

<https://www.science.org/toc/science/current>

Policy Forum

Getting genetic ancestry right for science and society

BY Anna C. F. Lewis, et al.

14 Apr 2022: 250-252

We must embrace a multidimensional, continuous view of ancestry and move away from continental ancestry categories

Science Translational Medicine

Volume 14| Issue 640| 13 Apr 2022

<https://www.science.org/toc/stm/current>

Reviews

Point-of-care diagnostic tests for tuberculosis disease

BY Jia Mei Hong, et al.

06 Apr 2022

Advances in biomarkers and microfluidics technology facilitate the development of TB disease diagnostic point-of-care tests.

Social Science & Medicine

Volume 294 February 2022

<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/294/suppl/C>

[Reviewed earlier]

Systematic Reviews

<https://systematicreviewsjournal.biomedcentral.com/articles>

[Accessed 16 Apr 2022]

[No new digest content identified]

Theoretical Medicine and Bioethics

Volume 42, issue 3-4, August 2021

<https://link.springer.com/journal/11017/volumes-and-issues/42-3>

Special Issue: A plea for an experimental philosophy of medicine

[Reviewed earlier]

Travel Medicine and Infectious Diseases

Volume 46 March–April 2022

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/46/suppl/C>

[Reviewed earlier]

Tropical Medicine & International Health

Volume 27, Issue 3 Pages: i-iv, 217-336 March 2022

<https://onlinelibrary.wiley.com/toc/13653156/current>

RESEARCH ARTICLES

[Reviewed earlier]

Vaccine

Volume 40, Issue 13 Pages 1913-2122 (18 March 2022)

<https://www.sciencedirect.com/journal/vaccine/vol/40/issue/13>

Review article Open access

[Epidemiology and economic burden of meningococcal disease in Germany: A systematic review](#)

S. Gruhn, J. Witte, W. Greiner, O. Damm, ... M. Knuf

Pages 1932-1947

Research article Open access

[Long-term effectiveness of human papillomavirus vaccines among adult women: A real-world scenario](#)

Ga Young Lee, Perapong Inthasorn, Piyawat Laowahutanont, Saranath Lawpoolsri, ... Punnee Pitisuttithum

Pages 1968-1976

Research article Full text access

[Promoting immunization equity in Latin America and the Caribbean: Case studies, lessons learned, and their implication for COVID-19 vaccine equity](#)

Isabella L. Chan, Robin Mowson, Juan Pedro Alonso, Javier Roberti, ... Martha Velandia-González

Research article Open access

[Impact of the Sinopharm's BBIBP-CorV vaccine in preventing hospital admissions and death in infected vaccinees: Results from a retrospective study in the emirate of Abu Dhabi, United Arab Emirates \(UAE\)](#)

Farida Ismail AlHosani, Anderson Eduardo Stanciole, Bashir Aden, Andrey Timoshkin, ... Farah Mustafa

Research article Open access

[Unmet need for COVID-19 vaccination coverage in Kenya](#)

Samuel K. Muchiri, Rose Muthee, Hellen Kiarie, Joseph Sitienei, ... Victor A. Alegana

Pages 2011-2019

Research article Full text access

[The correlates and dynamics of COVID-19 vaccine-specific hesitancy](#)

Eric Merkley, Peter John Loewen

Pages 2020-2027

Research article Open access

"On the last day of the last month, I will go": A qualitative exploration of COVID-19 vaccine confidence among Ivoirian adults

Natalie J. Tibbels, Abdul Dosso, Corinne Fordham, William Benie, ... Danielle A. Naugle

Pages 2028-2035

Research article Full text access

Public perceptions and the willingness to get vaccinated against COVID-19: Lessons from Israel

Oren Heller, Yung Chun, Yaniv Shlomo, Ateret Gewirtz-Meydan, ... Michal Grinstein-Weiss

Research article Open access

Conspiracy theories and misinformation about COVID-19 in Nigeria: Implications for vaccine demand generation communications

Chizoba Wonodi, Chisom Obi-Jeff, Funmilayo Adewumi, Somto Chloe Keluo-Udeke, ... Ruth Faden

Value in Health

April 2022 Volume 25 Issue 4 p473-676

<https://www.valueinhealthjournal.com/current>

[Reviewed earlier]

.....
.....

Pre-Print Servers

Gates Open Research

<https://gatesopenresearch.org/browse/articles>

Open Letter metrics AWAITING PEER REVIEW

Women's groups and COVID-19: An evidence review on savings groups in Africa [version 1; peer review: awaiting peer review]

Olayinka Adegbite, Leigh Anderson, Sybil Chidiac, Osasuyi Dirisu, Jenna Grzeslo, Julia Hakspiel, Chinmaya Holla, Emily Janoch, Krishna Jafa, Shubha Jayaram, Grace Majara, Tabitha Mulyampiti, Eve Namisango, Eva Noble, Bukola Onyishi, David Panetta, Garima Siwach, Munshi Sulaiman, Rebecca Walcott, Sapna Desai, Thomas de Hoop

Peer Reviewers Invited

Funder

The Bill and Melinda Gates Foundation

PUBLISHED 12 Apr 2022

medRxiv

<https://www.medrxiv.org/content/about-medrxiv>

medRxiv is a free online archive and distribution server for complete but unpublished manuscripts (preprints) in the medical, clinical, and related health sciences. Preprints are preliminary reports of work that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information. medRxiv is for the distribution of preprints - complete but unpublished manuscripts - that describe human health research conducted, analyzed, and interpreted according to scientific principles...

COVID-19 vaccine coverage among immigrants and refugees in Alberta: a population-based cross-sectional study

Shannon E MacDonald, Yuba Raj Paudel, Crystal Du

medRxiv 2022.04.11.22273644; doi: <https://doi.org/10.1101/2022.04.11.22273644>

Can We Really Trust the Findings of the COVID-19 Research? Quality Assessment of Randomized Controlled Trials Published on COVID-19

Athira S Joshy, Christy Thomas, Saphal Surendran, Krishna Undela

medRxiv 2022.04.15.22273881; doi: <https://doi.org/10.1101/2022.04.15.22273881>

Mondo: Unifying diseases for the world, by the world

Nicole A Vasilevsky, Nicolas A Matentzoglou, Sabrina Toro, Joe E Flack, Harshad Hegde, Deepak R Unni, Gioconda Alyea, Joanna S Amberger, Larry Babb, James P Balhoff, Taylor I Bingaman, Gully A Burns, Tiffany J Callahan, Leigh C Carmody, Lauren E Chan, George S Chang, Michel Dumontier, Laura E Failla, May J Flowers, H A Garrett Jr., Dylan Gration, Tudor Groza, Marc Hanauer, Nomi L Harris, Ingo Helbig, Jason A Hilton, Daniel S Himmelstein, Charles T Hoyt, Megan S Kane, Sebastian Kohler, David Lagorce, Martin Larralde, Antonia Lock, Irene Lopez Santiago, Donna R Maglott, Adriana J Malheiro, Birgit HM Meldal, Julie A McMurphy, Moni Munoz-Torres, Tristan H Nelson, David Ochoa, Tudor I Oprea, David Osumi-Sutherland, Helen Parkinson, Zoe M Pendlington, Ana Rath, Heidi L Rehm, Lyubov Remennik, Erin R Riggs, Paola Roncaglia, Justyne E Ross, Marion F Shadbolt, Kent A Shefchek, Morgan N Similuk, Nicholas Sioutos, Rachel Sparks, Ray Stefanicsik, Ralf Stephan, Doron Stupp, Jagadish Chandrabose Sundaramurthi, Imke Tammen, Courtney L Thaxton, Eloise Valasek, Alex H Wagner, Danielle Welter, Patricia L Whetzel, Lori L Whiteman, Valerie Wood, Colleen H Xu, Andreas Zankl, Xingmin A Zhang, Christopher G Chute, Peter N Robinson, Christopher J Mungall, Ada Hamosh, Melissa A Haendel

medRxiv 2022.04.13.22273750; doi: <https://doi.org/10.1101/2022.04.13.22273750>

There are thousands of distinct disease entities and concepts, each of which are known by different and sometimes contradictory names. The lack of a unified system for managing these entities poses a major challenge for both machines and humans that need to harmonize information to better predict causes and treatments for disease. The Mondo Disease Ontology is an open, community-driven ontology that integrates key medical and biomedical terminologies, supporting disease data integration to improve diagnosis, treatment, and translational research. Mondo records the sources of all data and is continually updated, making it suitable for research and clinical applications that require up-to-date disease knowledge.

Triangulating evidence in health sciences with Annotated Semantic Queries

Yi Liu, Tom R Gaunt

medRxiv 2022.04.12.22273803; doi: <https://doi.org/10.1101/2022.04.12.22273803>

Profile of Brazilian inpatients with COVID-19 vaccine breakthrough infection and risk factors for unfavorable outcome

Matheus Alexandre Santos de Jesus, Natália Satchiko Hojo-Souza, Thiago Rocha de Moraes, Daniel Ludovico Guidoni, Fernanda Sumika Hojo Souza
medRxiv 2022.04.12.22273589; doi: <https://doi.org/10.1101/2022.04.12.22273589>

Effectiveness of COVID-19 vaccines against hospitalization and death in Canada: A multiprovincial test-negative design study

Sharifa Nasreen, Yossi Febriani, Héctor Alexander Velásquez García, Geng Zhang, Mina Tadrous, Sarah A. Buchan, Christiaan H. Righolt, Salaheddin M. Mahmud, Naveed Zafar Janjua, Mel Krajden, Gaston De Serres, Jeffrey C. Kwong
medRxiv 2022.04.13.22273825; doi: <https://doi.org/10.1101/2022.04.13.22273825>

Health Economic Burden of COVID-19 in Saudi Arabia

Khalidah A. Alenzi, Hamdan S. Al-malky, Ali F. Altebainawi, Hamidah Q. Abushomi, Fahad O. Alatawi, Moosa H. Atwadi, Moosa A. Khobrani, Dlal A. Almazrou, Nariman Alrubeh, Zainab A. Alsoliabi, Abdulaziz M. Kardam, Shakr A. Alghamdi, Abdulrahman Alasiri, Thamir M. Alshammari
medRxiv 2022.04.08.22273439; doi: <https://doi.org/10.1101/2022.04.08.22273439>

Effectiveness of the BNT162b vaccine fourth dose in reducing SARS-CoV-2 infection among healthcare workers in Israel, a multi-center cohort study

Matan J Cohen, Yonatan Oster, Allon E Moses, Avishay Spitzer, Shmuel Benenson, the Israeli-hospitals 4th vaccine Working Group
medRxiv 2022.04.11.22273327; doi: <https://doi.org/10.1101/2022.04.11.22273327>

The relation between COVID-19 vaccinations and public governance to improve preparedness of next pandemic impacts and crisis management: a global study

Mario Coccia, Igor Benati
medRxiv 2022.04.10.22273663; doi: <https://doi.org/10.1101/2022.04.10.22273663>

Abstract

The goal of this study is to analyze the relationship between COVID-19 vaccinations and public governance performing a global analysis of more than 110 countries worldwide. Methodology applies the Independent Samples T-Test that compares the means of two independent groups (countries with high/low level of vaccinations) to determine whether there is statistical evidence that the associated population means of indicators of public governance are significantly different. Findings suggest that high levels of governance can support a better function of health systems in the rollout of vaccinations to cope with COVID-19 pandemic crisis. This study may assist long-run policy of governments to improve good governance and health systems of countries in order to reinforce the preparedness to face next pandemic threats and in general future crisis management in society.

Economic vulnerability and poor service delivery made it more difficult for shack-dwellers to comply with COVID-19 restrictions: The impracticability and inequitable burden of universal/unstratified public health policies

GTH Ellison, RB Mattes, H Rhoma, T De Wet
medRxiv 2022.04.07.22273499; doi: <https://doi.org/10.1101/2022.04.07.22273499>

COVID-19 vaccine for people who live and work in prisons worldwide: A scoping review

Nasrul Ismail, Lara Tavooschi, Babak Moazen, Alicia Roselló, Emma Plugge
medRxiv 2022.04.07.22273414; doi: <https://doi.org/10.1101/2022.04.07.22273414>

Novel Privacy Considerations for Large Scale Proteomics

Andrew C. Hill, Elizabeth M. Litkowski, Ani Manichaikul, Leslie Lange, Katherine A. Pratte, Katerina J. Kechris, Matthew DeCamp, Marilyn Coors, Victor E. Ortega, Stephen S. Rich, Jerome I. Rotter, Robert E. Gerzsten, Clary B. Clish, Jeffery Curtis, Xiaowei Hu, Debby Ngo, Wanda K O'Neal, Deborah Meyers, Eugene Bleecker, Brian D. Hobbs, Michael H. Cho, Farnoush Banaeikashani, Russell P. Bowler
medRxiv 2022.04.06.22269907; doi: <https://doi.org/10.1101/2022.04.06.22269907>

COVID-19 Vaccination Mandates and Vaccine Uptake

Alexander Karaivanov, Dongwoo Kim, Shih En Lu, Hitoshi Shigeoka
medRxiv 2021.10.21.21265355; doi: <https://doi.org/10.1101/2021.10.21.21265355> Revision

Acceptance of and preference for COVID-19 vaccination in healthcare workers: a comparative analysis and discrete choice experiment

Chuanxi Fu, Zheng wei, Fengchang Zhu, Sen Pei, Shunping Li, Liuren Zhang, Xiaohui Sun, Yue Wu, Ping Liu, Mark Jit
medRxiv 2020.04.09.20060103; doi: <https://doi.org/10.1101/2020.04.09.20060103> Revision

SARS-CoV-2 reinfections with BA.1 (Omicron) variant among fully vaccinated individuals in the northeast of Brazil

Francisco P. F. Neto, Diego G. Teixeira, Dayse C. S. da Cunha, Ingryd C. Morais, Celisa P. M. Tavares, Genilson P. Gurgel, Sanderson D. do Nascimento, David C. dos Santos, Alexandre de O. Sales, Selma M.B. Jerônimo
medRxiv 2022.04.08.22272726; doi: <https://doi.org/10.1101/2022.04.08.22272726>

Wellcome Open Research [to 16 Apr 2022]

<https://wellcomeopenresearch.org/browse/articles>

[Accessed 16 Apr 2022]

Wellcome Open Research provides all Wellcome researchers with a place to rapidly publish any results they think are worth sharing. All articles benefit from rapid publication, transparent peer review and editorial guidance on making all source data openly available.

Data Note metrics AWAITING PEER REVIEW

An open dataset of *Plasmodium vivax* genome variation in 1,895 worldwide samples

[version 1; peer review: awaiting peer review]

MalariaGEN, Ishag Adam, Mohammad Shafiul Alam, Sisay Alemu, Chanaki Amaratunga, Roberto Amato, Voahangy Andrianaranjaka, Nicholas M Anstey, Abraham Aseffa, Elizabeth Ashley, Ashenafi Assefa, Sarah Auburn, Bridget E Barber, Alyssa Barry, Dhelio Batista Pereira, Jun Cao, Nguyen Hoang Chau, Kesinee Chotivanich, Cindy Chu, Arjen M. Dondorp, Eleanor Drury, Diego F. Echeverry, Berhanu Erko, Fe Espino, Rick Fairhurst, Abdul Faiz, María Fernanda Villegas, Qi Gao, Lemu Golassa, Sonia Goncalves, Matthew J Grigg, Yaghoob Hamed, Tran Tinh Hien, Ye Htut, Kimberly J Johnson, Nadira Karunaweera, Wasif Khan, Srivicha Krudsood, Dominic P Kwiatkowski, Marcus Lacerda, Benedikt Ley, Pharath Lim, Yaobao Liu, Alejandro Llanos-Cuentas, Chanthap Lon, Tatiana Lopera-Mesa, Jutta Marfurt, Pascal Michon, Olivo Miotto, Rezika Mohammed, Ivo Mueller, Chayadol Namaik-larp, Paul N Newton, Thuy-Nhien Nguyen, Francois Nosten, Rintis Noviyanti, Zuleima Pava, Richard D Pearson, Beyene Petros, Aung P Phyto, Ric N Price, Sasithon Pukrittayakamee, Awab Ghulam Rahim, Milijaona Randrianarivelojosia, Julian C Rayner, Angela Rumaseb, Sasha V Siegel, Victoria J Simpson, Kamala

Thriemer, Alberto Tobon-Castano, Hidayat Trimarsanto, Marcelo Urbano Ferreira, Ivan D Vélez, Sonam Wangchuk, Thomas E Wellems, Nicholas J White, Timothy William, Maria F Yasnot, Daniel Yilma
Peer Reviewers Invited
Funders
Wellcome Trust
Medical Research Council UK and the Department for International Development (DFID)
Bill and Melinda Gates Foundation
PUBLISHED 14 Apr 2022

Research Article metrics

Revised

[Stage 2 Registered Report: How responsibility attributions to self and others relate to outcome ownership in group decisions](#) [version 2; peer review: 2 approved]

Matt Jaquiery, Marwa El Zein

Peer Reviewers John A. Dewey; Nura Sidarus

Funders

Wellcome Trust

Medical Research Council

University of Oxford

LATEST VERSION PUBLISHED 11 Apr 2022

Research Article metrics

Revised

[A survey to gather perspectives of DBT/Wellcome Trust India Alliance-funded researchers on public engagement with science](#) [version 2; peer review: 2 approved]

Sarah Iqbal, Banya Kar

Peer Reviewers Marina Joubert; Mary Chambers and Han Dong Thai Tran

Funder

DBT/Wellcome Trust India Alliance

LATEST VERSION PUBLISHED 08 Apr 2022

*

*

*

*

Think Tanks

Brookings

<http://www.brookings.edu/>

Accessed 16 Apr 2022

[No new digest content identified]

Center for Global Development [to 16 Apr 2022]

<https://www.cgdev.org/>

Research [Selected]

POLICY PAPERS

[Beyond India's Lockdown: PMGKY Benefits During the COVID-19 Crisis and the State of Digital Payments](#)

Alan Gelb et al.

April 11, 2022

India imposed a lock-down in response to the COVID-19 pandemic in March 2020 and began a gradual re-opening in June. A telephonic survey in April examined the early effectiveness of information and the massive PMGKY social protection program (Policy Paper 217). This paper analyzes a second-round sur...

Chatham House [to 16 Apr 2022]

<https://www.chathamhouse.org/>

Accessed 16 Apr 2022

[No new digest content identified]

CSIS

<https://www.csis.org/>

Accessed 16 Apr 2022

Upcoming Event

[Equity in Immunization Services to Ensure "A Long Life for All"](#)

April 28, 2022

Upcoming Event

[Innovation and IP's Role in Combatting the Covid-19 Pandemic](#)

April 27, 2022

Upcoming Event

[AMR as a Global Security Threat: Destabilizing Food Systems and Healthy Communities](#)

April 25, 2022

Commentary

[Removing Patent Rights to Lower Drug Costs Is a Dangerous Precedent](#)

April 14, 2022 | By [Walter G. Copan](#)

Kaiser Family Foundation

https://www.kff.org/search/?post_type=press-release

Accessed 16 Apr 2022

Accessed 16 Apr 2022

[No new digest content identified]

ODI [Overseas Development Institute] [to 16 Apr 2022]

<https://odi.org/en/publications/>

Publications

Accessed 16 Apr 2022

[No new digest content identified]

Rand [to 16 Apr 2022]
<https://www.rand.org/pubs.html>
Reports, Selected Journal Articles
Report

How Extremism Operates Online: A Primer

In this Perspective, the second in a RAND Corporation series on online extremist material, the authors explore how the internet affects extremist activities and how exposure to or consumption of such content influences the behavior of internet users.

Apr 12, 2022

Alexandra T. Evans, Heather J. Williams

* * * * *
* * * * *

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy ([CVEP](#))/GE2P2 Global Foundation, which is solely responsible for its content.

.....

Copyright GE2P2 Global Foundation 2022. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/> or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation The Rockefeller foundation, Boston University, or 3-D Commission logos is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

.....

CVEP is a program of the [GE2P2 Global Foundation](#) whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the [Bill & Melinda Gates Foundation](#); the Bill & Melinda Gates Medical Research Institute , [PATH](#), and industry resource members Janssen/J&J, Pfizer and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

*	*	*	*
*	*	*	*